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intravenous exposure of low doses of gadodiamide in the brains of
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Candidate for Degree of Master of Science
Proton MR spectroscopy is a tool that provides quantified brain bioprofiles. Two
methods exist: single- and multi-voxel spectroscopy. No studies compare their clinical
validity in vivo. Gadolinium based MR contrast agents are used to improve lesional
conspicuity. Adverse events are reported. Brain deposition occurs following
administration in people and murine models. In dogs, doses are anecdotal and deposition
is not described. Eight normal dogs underwent MRI at 3 Tesla with two methods of
spectroscopy and were administered varying doses of gadodiamide. No differences were
seen between single- and multi-voxel spectroscopy when interrogating identical regions
of interest. Brains were harvested and evaluated for gadolinium depots using inductively
coupled plasma mass spectrometry. Gadolinium was found in the brains of all dogs with
dose dependency. Further, adequate normal brain conspicuity was seen at a dose of 0.5
mmol/kg. Thus, clinical trials of gadolinium chelated contrast agents at this dose are
recommended.
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CHAPTER I
INTRODUCTION TO MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY
Magnetic resonance imaging (MRI)
The use of magnetic resonance (MR) imaging (MRI) in humans has grown
exponentially over the past few decades, in part due to the excellent anatomical and
pathological detail provided by this modality.1,2 The use of contrast enhanced MRI in
veterinary medicine is no exception, and a growing number of veterinary patients have
benefited and continue to benefit from the clinical use of this imaging modality. This
growth is in part due to a growing understanding of the capabilities of the imaging
modality as fostered by the American College of Veterinary Radiology (ACVR), its
growing number of diagnostic imaging specialists, and a client base of pet owners willing
and financially able to pursue this advanced technology through tertiary care referral
centers and academic institutions.
With regard to brain imaging in particular, important and generally accepted
advantages of conventional MRI over the use of computed tomography (CT) include the
ability to directly acquire images with different sequences that exploit specific tissue
contrasts, the ability to avoid beam hardening artifacts in regions of high bone density
(such as the petrous temporal bone for evaluation of the pons, cerebellum and structures
within the caudal fossa), and the ability to obtain detailed differentiation of gray-white
matter tissue and ventricular structures. In addition to routine conventional MR sequence
1

protocols, there are more advanced applications, such as MR spectroscopy, vascular
angiography (time of flight imaging or MR angiography), volumetric imaging, blood
oxygen level dependent imaging and diffusion/perfusion weighted imaging, which can be
performed to gain additional biomolecular and functional information beyond that of
simple brain morphology and pathology.
Historical background
A complete overview of the history of nuclear magnetic resonance (NMR)
imaging (NMRI) is beyond the scope of this thesis, and compiled histories can be found
in numerous publications.3-7 The following is an abridged account of the historically
significant milestones that contributed to the great success of MRI as one of the most
valuable clinical imaging modalities of our era.
Isidor Rabi of Columbia University first described nuclear magnetic moment
“beams” in 1938 and was awarded the Nobel Prize for his discovery.4,5 In the late 1940s,
nuclear magnetic resonance became the focus of experimental exploration of physicists
and chemists of that period. From 1946–1952 teams at Cambridge, Stamford and
Massachusetts Institute of Technology (MIT) worked simultaneously, yet independently,
toward the discovery of nuclear magnetic resonance imaging.3 Block (of Stamford) and
Purcell (of MIT) won the Nobel Prize for physics in 1952 for their achievements and now
famous prior publications.3,8,9 Around the same time (1950), Proctor, Yu and Dickinson
were the first to discover that nuclei within the same atom absorbed energy at different
resonance frequencies, while Shaw and Elksin were investigating the water content of
vegetables.3,4,10-12 For 20 years, physicists, chemists and biologists explored molecular
compounds and chemical structure (both in and ex vivo) using the basic magnetic
2

resonance principles proposed earlier. By the late 1950s, approximately 400 papers on the
topic had been published, and the first established text about NMR made reference to all
of them.3,13
In 1955, Odeblad and colleagues pioneered investigations on animal and human
tissues and fluids, which lead to numerous biologic investigations on the molecular
characteristics of vitreal and lenticular fluids, blood cells, spinal fluid, saliva and muscle
tissues.14 By 1966, Ernst and Anderson introduced pulsed MR and Fourier
transformation.15 Investigations on whole organisms (ranging from bacteria to rodents),
and later human subjects, naturally followed; however, it was not until the early 1970s
that Raymond Damadian first proposed the medical use of NMR and hypothesized that
NMR could be used to differentiate between abnormal or cancerous tissues and normal
tissues.4,16 He patented his concept and later created the first whole body NMRI machine.
Early in the same decade (1973), in Stony Brook, New York, Lauterbur, Mansfield and
Grannell used magnetic gradients to produce the first images of live animals,
demonstrating the NMR properties of tissue for which Lauterbur and Mansfield later
shared the Nobel Prize in medicine (2003).4,6 Lauterbur called this technique
zeumatography, which in Greek means “that which joins together.”6 In the late 1970s,
publications applying methods of spatial localization began to surface using sequential
point, line scanning, production-reconstruction and two- and three-dimensional Fourier
transformation began to surface.6 These techniques were, and still are, used to display
slice images and achieve second and third planar imaging. Although essential to image
production, a full discussion these techniques is beyond the scope of this work.

3

Detailed internal images of biological structures of fruits, vegetables, members of
the animal kingdom (such as clams, mice, and rabbits) and eventually the first human
MRI of a finger were published.16-18

3T magnetic resonance images of a “brainy” orange
A and B– “Dorsal” and “transverse” planar images T2-weighted images. C– “Transverse”
planar proton density image. D– “Transverse” planar gradient echo image. Notice the
susceptibility artifact (black within the image) within the orange due to trapped gas. E–
Diffusion tensor image, a measure of Brownian water molecular motion demonstrating
free water movement along the “pathways” of least resistance of (hyperintense regions)
and restricted regions, or membrane boundaries. Courtesy J. Gambino and G. Sorrells –
we scan our lunch.
The low field images (on the order of 0.15T) showed different contrasts of
different tissues, which arose from inherent properties of the object’s construction like
tissue density, mobility and relaxation.16 The first images of the human thorax, head and
abdomen of healthy volunteers preceded early images of the first descriptions of
pathology in 1980s.19-21 Early diagnostic capabilities included the recognition of
4

hydrocephalus, a variety of intracranial tumors, aneurysms, arteriovenous fistulas and
chronic sinustits.6
The first high field, superconducting, MRI machine was installed by Oxford
Instruments in London, at Hammersmith Hospital in 1981, with commercial magnets
coming into use at clinical facilities shortly thereafter.7 MRI has become a staple of
clinical human and veterinary radiology with incredible advances occurring between its
advent in the early clinical use in the 1980s to today. The rapidly progressive interest of
in vivo applications of this technology, in areas such as microimaging, spectroscopy,
functional brain imaging and interventional imaging, have brought MRI to the forefront
of medical imaging.
Basic principles of nuclear magnetic resonance
In order to discuss the clinical applications of MRI, contrast-enhanced imaging,
and magnetic resonance spectroscopy (MRS), a basic understanding of MRI physics is
essential.
Classical and quantum MRI physics
Two methods of physics are used to describe the NMR phenomena. In the
classical description, molecular momentum is described in the reference frame of
classical Newtonian derivatives. Vectors of magnitude, direction and frequency are used
to explain the relationships between angular momentum, magnetic moment and the
inherent spin of the nuclear components of elements. The motion of an object’s molecular
construct (in the case of MRI, nuclear particles, for example 1H), is linear or rotational
and its corresponding momentum is linear or rotational.4 The particle’s motion can be
5

thought of as its tendency to remain in motion. In accordance with Newton’s second law
of motion, only a force can disrupt this tendency. Molecules may also have momentum at
an angle, which can only be affected by the force of torque (or rotational force). At the
same time it must be considered that such rotating objects have a charge, such that when
in motion, according to Faraday’s law of induction, an electrical current loop is created
inducing a magnetic field.7 This magnetic field is characterized by a fundamental
magnetic quantity associated with current, called a magnetic dipole moment. With regard
to any periodic orbital motion, there is a fundamental relationship between magnetic
moment and angular moment where the magnetic dipole moment is the object’s inherent
classical gyromagnetic ratio.7 Thus, any time there is magnetism, charge and momentum,
any two will induce the third.
Quantum mechanical theory and classical arguments arrive at the same
relationship, where the magnetic dipole moment is inversely proportional to the
gyromagnetic constant (characteristic to the nucleus under investigation) multiplied by
the angular momentum of the spinning particle.7

6

Quantum mechanics model
Diagram depicting the quantum mechanics model. Discreet energy absorption is shown
over time, as the energy differences between the spin-up (blue) and spin-down (red)
conditions. Discreet absorption of quanta of energy cause the protons to excite from
alignment with the main magnetic field (spin-up or B0) to the spin-down condition. This
phenomenon is the origin of the signal that contributes to image creation. Adapted from
Bushberg, The essential physics of medical imaging,7
In the author’s opinion, a classical explanation falls short especially with regard to
MR spectroscopy because it does not fully explain the intimate relationship between
magnetic energy associated with magnetic moment and the general resonance condition.4
A quantum mechanical discussion is the only theory that can completely describe NMR
phenomenon because it takes into consideration the amplitude of the spin of an
elementary particle which is finite and limited, as well as its directions, which are discreet
and specific.7 Furthermore, it takes into account changes in energy that the particles
undergo and discusses the changes in terms of electromagnetic waves and nuclear spins.
7

Basic spin theory and net magnetization
In quantum mechanics, protons, neutrons and electrons have a spin quantum
number that can be calculated using atomic mass and charge number under the following
few summarized rules.7 For nuclei with odd atomic mass, spin quantum number is a half1

3

integral.4,7 Examples include 1H and 13C for which spin quantum numbers are 2 and 2
respectively.7 For nuclei with even atomic mass and even charge, spin quantum number
is zero with examples including 12C and 16O.7 For nuclei with even atomic mass and odd
charge, spin quantum number is an integral number.7 For example, the spin quantum
number for 2H and 14N are 1 and 2, respectively.7
1

For the hydrogen proton (1H), 2 energy states exist: quantum spin +2 and quantum
1

spin –2.4,7,22 The quantum theory describes these as spin up positions (or the low energy
alpha spin state) and spin down position (or the high energy beta spin state). In a high
field magnet, the lower energy (or spin up) state predominates with magnetic moments
parallel to the main magnetic field, whereas the beta spin state has an antiparallel angular
momentum.4,7 Between the two states exists an energy difference with the energy being
greater in the spin down position.4,7 With regard to clinical MRI and image acquisition, a
radiofrequency (RF) pulse is applied to manipulate the particles that are aligned in a main
magnetic field of the magnet in order to generate the NMR phenomenon of precession.
The energy of the applied oscillating magnetic field (or electromagnetic wave or RF), is
equal to that of the energy difference between the spin up and spin down states.4,7
In living systems in which we investigate 1H, the low energy state predominates
in that a greater population of protons is in the spin up state aligned with the main
8

magnetic field (B0). For a macroscopic sample of living tissue containing one million
nuclear spins at 3T, corresponding with the velocity of spin of 400 Mhz, the population
difference between the two states is small, only 37–67 spins or 0.006%. The final signal
received is proportional to this population difference and is the signal that contributes to
final image construction and the perception of different tissue contrasts. MRI and MRS
are far less sensitive when compared to other forms of spectroscopy (like mass
spectroscopy) where the energy differences are much larger.4 Total signal is dependent
however, on many factors (some predictable and some not) including sample volume,
gyromagnetic ratio, temperature, natural abundance of the nucleus studied, (sample)
noise, relaxation parameters and inherent tissue characteristics, the presence of artifact
inducing conditions, the presence of relaxation enhancing contrast agents and magnetic
field strength4.
MRI images are made based on the electromagnetic activity of 1H within the
body. Human bodies, and those of the mammalian species are predominantly composed
of water. 1H is very abundant in tissues. Protons and neutrons within atomic nuclei both
have linear and rotational (spin) motion and momentum (or electromagnetic moment).
The spins of the nuclear particles each have an individual axis and generate small internal
magnetic fields with unchanging or constant linear momentum and speed.7 Momentum
changes (acceleration and deceleration) result only when an external force is applied as
per basic Newtonian principals. MR imaging is based on the concept of this nuclear spin
being influenced by externally applied magnetic fields and radiofrequencies. When under
the influence of a strong magnetic field and exposed to such radiofrequencies, these
nuclei absorb and emit energy and undergo changes in angular (or directional)
9

momentum. Fluctuations in angular momentum from radiofrequency manipulations result
in the superior soft tissue contrast resolution of the images.
The Larmor equation
Under normal circumstances, the spinning of the protons and neutrons in our
bodies is a random event. Although we are “magnetized,” the magnetism of the Earth’s
magnetic field (on the order of 50 µT) is too small to have much of an effect. The highfield magnet at the author’s institution is a 3T magnet (on the order of 60,000 times the
Earth’s gravitational force).7
The abundance of water in the human body makes the 1H isotope almost 100%
ubiquitous. 1H also has the highest magnetic moment among stable nuclei.7,13 Oxygen is
the next most abundant element, but it is not one to investigate given its lack of a suitable
isotope and the artifacts it imparts on images.3 Phosphorus (31P) is also 100% abundant
with high magnetic moment. However, its concentration in living organisms is low. The
abundance of carbon is less (approximately 1%) and its magnetic moment is very low
making it unfavorable and difficult to exploit.4 Nitrogen isotopes are also unsuitable,
having either low abundance or magnetic moment.3 Other compounds are used in
research applications, but have a lower NMR sensitivity than 1H. For example, 19F is
abundant, but has 83% of the MR sensitivity of 1H.23

10

Table 1.1

Magnetic moments of medically useful nuclei

Nucleus

Magnetic Moment

1

H

2.79

3

He

–2.13

13

C

0.70

17

O

–1.89

19

F

2.63

23

Na

2.22

P

1.13

31

Magnetic moment given in units=5.05 x 10–27 J T–1
When living systems are placed in a clinical MR unit, it is 1H that is exploited
given its abundance, concentration and angular momentum. When the protons are
exposed to a large magnetic field, the two magnetic fields, those of the externally applied
B0, and those of the nuclei, interact. When they interact, the protons become still
momentarily and shortly thereafter begin to regain movement or precess. This precession
occurs at a frequency (ω0), which is dependent on the strength of the external magnetic
field. The Larmor equation
𝝎𝟎 = 𝑩𝟎 ∗ 𝜸

(2.1)

defines the frequency at which precession occurs. The magnitude of B0 is expressed in the
unit Tesla. Gamma () is the gyromagnetic ratio measured in MHz per Tesla, which is a
constant for every atom at a given magnetic field strength (as given in Table 1.2).24
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Table 1.2

Gyromagnetic ratios for medically useful elements in MR

Nucleus

Gyromagnetic Ratio (MHz/T)

1

42.58

H

13

C

10.7

17

O

5.8

19

F

40.0

23

Na

11.3

P

17.2

31

Excitation and magnetization vectors
Because of the abundance of 1H protons in the body, when placed under the
influence of B0, the majority of the protons align with that main externally applied field
and become a separate magnetic or static net magnetization vector. A second externally
applied force, B1 (or RF pulse) is then applied. This RF pulse, induces a flip or inversion
of the net magnetic vector away from the main magnetic field (B0, or in the classical
description, the Mz vector) and into the longitudinal and transverse planes (the Mx and My
fields, respectively).7 As the transverse vector precesses around the receiver coil, it
induces a current, as described in the previous section, and in accordance to Faraday’s
law of induction.20
Nuclear magnetization can only be observed by rotating the net magnetization
onto the transverse plane and inducing precessions about the B0 and B1 axes.4 Both
magnetic fields act simultaneously at the Larmor frequency and induce an electromotive
12

force in the receiver coil surrounding the sample.4 A 90o pulse is applied, which moves
the protons into the transverse vector resulting in a maximum Mxy. These protons are said
to be in phase coherence. Intrinsic inhomogeneity in the tissues causes a loss of Mxy. This
is called the free induction decay (FID). We described earlier that the subsequent current
that the magnetization induces becomes the MR signal.21
Free induction decay
As described, externally applied RF pulses force the protons out of thermal
equilibrium (which occurs in the direction of Mz / B0 and is the natural state of the
protons when tissues are placed in a strong magnetic field). The RF is then turned off,
and the protons are again free to precess to their original states (and realign with B0). This
process is called free induction decay (FID) and it occurs in both the transverse and
longitudinal planes (Mx, My).19 The term decay refers to a relaxation of the protons from
the excitable state due to the RF pulse and a subsequent decrease in signal intensity.
Decay in the longitudinal plane is referred to as T1 (spin-lattice) relaxation, whereas
decay in the transverse plane is referred to as T2* and T2 (spin-spin) relaxation.7
Transverse and longitudinal decay occur simultaneously. Different tissues within the
body and in the brain have different T1, T2* and T2 relaxations.
Free induction decay (FID) is an important component to the creation of MR
spectral (or Lorentzian absorption and dispersion) line shapes. Following excitation,
transverse magnetization occurs at 𝜔0 and decays with a characteristic time constant or
T2* as time progresses. Complex three-dimensional FID can be described by two
projections of the motion, the Mx t (a real component) and iMy t (an imaginary
component), where t is the characteristic time constant for the loss of phase coherence
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amongst the spins.4 Although this FID is often presented as a single-exponential decay,
local magnetic field inhomogenieties cause small variations in individual spin decays,
which results in a multi-exponential decay pattern.
Signal localization and magnetic field gradients
Acquisition of MR images and signal detection by the MRI machine, inherent
computer components and software are complicated processes. Detection of signal
location is by way of a complicated extrapolation from gradients along the x, y and z axes
and a mathematical process called Fourier Transformation, which translates the data
obtained into a visible image in a domain called k-space.22 The acquisition gradients are
termed slice selection (SSG), phase encoding (PE) and frequency encoding (FE)
gradients.22 The slice selection gradient selects the target region of the RF pulse, and the
steeper the gradient, the thinner the slice. Phase encoding occurs along the y-axis or
longitudinal gradient. Frequency encoding (also called the read out gradient because it
usually occurs when the echo is read out), occurs along the transverse or x-axis.22
Fourier transformation and image generation
Once the MRI computer processor has all the information about the proton spins
occurring in each of these planes, it can then compute the exact location and amplitude of
the signal. This information is then stored in k-space, which is a matrix of voxels within
which the raw imaging data resides.7 The center of k-space usually stores information
regarding the gross morphology and tissue contrast, whereas the periphery of k-space
stores information about the details of fine structures (or spatial resolution).17 The raw
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data must then be Fourier transformed in order to display the typical MRI image seen on
a computer monitor used for diagnostic evaluation.17
Tissue contrast
Two parameters in particular contribute to differences in contrast seen between
the tissues on MRI images. These are time to echo (TE) and time to relaxation (TR). TR
is the time in milliseconds between the application of the RF pulse and the start of the
next RF pulse.19 TE is the time in milliseconds between the start of the RF pulse and the
peak of the echo detected.19 Most pathologies have high signal intensity due to the density
of their proton content and hence have high signal intensity on T2.
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Table 1.3

MR signal intensity characteristics of various tissues

Signal Intensities

T1

T2

Signal Intensities

Hypointense

Air

Hypointense

(dark, black, or

Bone

(dark, black, or

signal void)

Calcifications/stones

signal void)

Fast flowing blood
Isointense

Ligaments, tendons, scars

Isointense

(medium grey)

High bound water tissues

(medium grey)

Liver, pancreas, adrenal glands, hyaline
cartilage, muscle
Edema/fluids

Bone islands

Urine, bile, cystic
fluid, cerebrospinal
fluid
High free water
tissues
Kidneys, spleen
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Table 1.3 (Continued)
Hyperintense

Proteinaceous fluid

Hyperintense

(light grey to white)

Abscess, complex cyst, synovial fluid

(light grey to white)

Fat

Edema/fluids

Bone marrow

Urine, bile, cystic

Methemoglobin

fluid, cerebrospinal

Slow flowing blood

fluid

Paramagnetic

High free water

contrast

tissues
Kidneys, spleen
Blood products
Oxyhemoglobin
Extracellular
methemoglobin

T1-weighted and T2-weighted signal characteristics of various tissues. The shared T1 and
T2 characteristics are placed in the centered cell, while different characteristics between
T1 and T2 are placed in the divided cells. Table Adapted from Bitar et. al.24
Proton magnetic resonance spectroscopy
Although the MR appearance of multiple disease processes of the brain, including
neoplastic, infectious, and immune-mediated disorders, have been well described in both
human and veterinary literature, the specificity of MRI for definitive diagnoses remains
limited.25-28 In people, the sensitivity of MR for brain tumor diagnosis is reportedly 95%–
99%, whereas the specificity is 70%–76%.25,29 This relatively low specificity is due to
signal overlap in MR imaging characteristics and lesion morphology between various
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disease etiologies (and is seen in both people and dogs).26,29 When spectroscopy is added
to conventional MR imaging interpretation, the sensitivity for disease detection is
reportedly 80%–100% and the specificity increases to 78%–100%.30,31
Metabolites of interest
Magnetic resonance spectroscopy (MRS) is a non-invasive, U.S. Food and Drug
Administration (FDA)-approved, complementary MR imaging technique which allows
for the interrogation of numerous inherent tissue biological markers.32 With regard to the
brain, biomarkers of interest typically include N-acetyl aspartate (NAA), creatine (Cr),
choline, (Cho), myo-inositol (mI), lactate (Lac), lipids, glutamine-glutamate complex
(Glx), and taurine (Tau).32,33 MRS allows for the in vivo quantization of these markers,
thus providing qualitative and quantitative data regarding the metabolic and functional
status of the imaged tissue; which conventional MR acquisition pulse sequences do not
provide.32,34 Spectroscopic data can be particularly useful in acting as a complement to
conventional MR images in improving interpretation accuracy in the brain.34-36 As stated
above, the addition of spectroscopy can increase the sensitivity of the scan to 80%–100%
and the specificity of the scan to 78%–100%.30,31
Briefly, lipids (which resonate at a ppm of 0.9–1.4) are products of brain
destruction.31 Lactate, which resonates at 1.3 ppm, is a product of anaerobic glycolysis,
and is increased in cases of meningoencephalitis.31 N-acetyl aspartate (NAA), which
resonates at a ppm of 2.0, is a neuronal marker present in neurons, axons, and dendrites,
representing axonal number and dendritic and axonal density. The NAA fraction is
decreased in tumors, including gliomas and meningiomas, as well as hepatic
encephalopathy.31,37,38 The glutamine-glutamate complex (Glx complex), which resonates
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at 2.2–2.4 ppm, is composed of two neurotrasmitters.31 Glutamine is involved in
detoxification and regulates neurotransmitter activity. Glutamate is excitatory and is
involved in mitochondrial metabolism.31 Increases in fractions of the Glx complex can be
seen with traumatic brain injury, oligodendroglioma, and epilepsy.39,40 Creatine (Cr,
which resonates at 3.0 ppm) is involved in energy metabolism and is increased in hepatic
encephalopathy.31,38 Choline (Cho), which resonates at 3.2 ppm, is a cell membrane
marker and is involved in cellular synthesis and degradation. It is elevated in gliomas and
meningioma but is decreased in hepatic encephalopathy and can also be elevated in
certain inflammatory conditions.31,37,38 Resonating at 3.5 ppm, myo-inositol (mI) is a
pentose sugar and is a glial cell marker involved in the triphosphate intracellular second
messenger system.31 This metabolite may be elevated in extra-axial choroid plexus
tumors, in gliosis, in Alzheimer’s disease in people, or following the administration of
mannitol.31,34 Alanine, an amino acid, (resonating at 1.48 ppm) is present and typically
seen in meningiomas.31 Taurine (3.4 ppm) is an osmoregulator and a moderator of
neurotransmitter action and can be elevated in high grade malignancies.31 Please refer to
Appendix B for more information regarding these metabolites. Tables of common
elevations in disease states in people and animals are given below.
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Table 1.4

Common metabolite changes in non-neoplastic disease states in people

Disease

mI

Cho

Lac

Lip

Succinate

ND

+

+

ND

+

+

ND

Subacute
infarct

+

Focal cortical
dysplasia

++

Pyogenic
abscess

+

Delayed
radiation
necrosis
Peritumoral
edema
Herpes
encephalitis

+

++

Arachnoid
cyst

++

Epidermoid
cyst

++

Hydatid cyst

++

Toxoplasmosis

+

ND=none detected. Adapted from Kingsley et al.41
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Table 1.5

Common metabolite changes in neoplastic disease states in people
Cho

Lac

Lip

Pilocytic Astrocytoma

+

ND

ND

Diffuse Astrocytoma

+

ND

ND

Oligodendroglioma

+++

ND

ND

Anaplastic
Astrocytoma

+++

+

ND

GBM

+++

+

+

Ependymoma

+++

ND

ND

Medulloblastoma

+++

ND

ND

Meningioma

+++

ND

ND

Metastasis

++

ND

++

+++

++

++

Disease

Lymphoma

mI

++

ND=none detected. Adapted from Kingsley et al.41
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Table 1.6

Common metabolite changes in non-neoplastic disease states in animals

Disease

mI

Cho

Cr

Glx

NAA

–

+

–

–

ND

+

–

–

–

Feline
immunodeficiency
virus
Canine hepatic
encephalopathy

–

Abscess (caprine)

–

Canine
noninfectious
meningoencephalitis

Lac

Lip

Succ Tau

+

+

+

+

+

Succ=succinate. ND=none detected. Adapted from Carrera et al 2014,38 Carrera et al
2016,42 Power et al,43 and Dennler et al.44
Table 1.7
Disease

Common metabolite changes in neoplastic disease states in dogs
mI

Cho

Cr

NAA

Lac

Lip

Glioma

+++

–

+

+

Meningioma

+++

–

+

+

Adapted from Stadler et al.37
Metabolites may be present in increased or decreased concentrations, or may be
absent all together in varying pathologic conditions.33 Many of these conditions can have
overlapping biomarker signal intensities and similarities in their respective brain
bioprofiles, such that accurate interpretation only comes from evaluation of the clinical
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presentation, the conventional MR images, and functional MR imaging, if performed
(Jennifer Gambino, personal communication, January 17, 2017). With regard to human
brain tumors, it is common to see elevations in Cho, lactate, and lipids, while there is
usually a decrease in NAA and Cr.31 A metabolite not normally present in brain tissue is
lactate, and lactate may be seen in increased concentrations in varying pathologic
conditions such as neoplasia, ischemia and coagulative necrosis.33 In the author’s
experience, in the dog, mild to moderate Lac/Lip fraction elevations seen in conjunction
with mild Cho and Cr depression and lack of moderate NAA depression, can make
infarction distinguishable from intra-axial tumors (specifically of glial cell origin) in
which Cho and NAA depression trends are noted. (Gambino unpublished data).
Acquisition of MRS
MRS is typically performed following the acquisition of a complete study of
conventional morphologic brain MR images. Magnet shimming, to correct for magnetic
field inhomogeneities is essential in spectroscopic acquisitions. Additionally, water
suppression must be performed, because the concentration of water in biological samples
is much higher than the metabolites in question. If water suppression is not performed,
the water peak would be much larger (up to 100,000 times that of water) than the
metabolites, and the necessary scaling would make the metabolite peaks impossible to
see.4 Water suppression is accomplished by either a chemical shift selective (CHESS) or
inversion recovery (IR) technique, coupled with a stimulated echo acquisition mode
(STEAM) or point resolved spectroscopy (PRESS) acquisition.4,22 An MRS pulse
sequence is applied, and the resultant data is displayed as a set of signal peaks derived
from the inherent quantum spin of the metabolites of interest.45 This data is what forms
23

the spectrum. The spectral data is presented in graphical format with two axes. The
vertical y-axis corresponds to signal intensity, which is given in arbitrary units (machine
or MACH units for single-voxel acquisitions and relative or absolute machine units for
multi-voxel acquisitions). These units correspond closely to the number of millimoles
(mmols) of atoms (versus the molar concentration of water). The concentration of these
atoms can then be presented as either a general proprietary MACH unit, an absolute
value, or as a value relative to the concentration of water in the imaged tissue depending
on the MRS probe acquisition applied. With regard to the bioprofile, the horizontal x-axis
corresponds to frequency, given in either absolute (Hertz, Hz) or relative (parts per
million, ppm) measure.32 Generally, Hz units are converted to ppm because of differences
in the Hz values for metabolites between magnets of different field strength.46,47 The ppm
for metabolites remains constant for molecules, because the separation in Hz is
proportional to field strength.46,47 The equation for the conversion of Hz to ppm is given
by:
𝒅𝒇 =

𝒇 × 𝒑𝒑𝒎
𝟏𝟎𝟔

(2.2)

where df is the peak frequency in Hz, ppm is the peak variation, and f is the center
frequency of the metabolite in Hz.
As described above, specific metabolites have inherent (fingerprint) quantum
spins, which correspond to frequency shifts relative to a frequency standard, given in
ppm, on the horizontal axis. The frequencies for these metabolites of interest are well
described in the literature and allow for identification of these metabolites on the x-axis
of the spectrum.31,32 The signal measured from the imaged tissue depends on a variety of
factors, including magnet strength, voxel size, pulse sequence, echo times, number of
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signal averages, and T1 and T2 relaxation times.33 Due to these confounding factors,
metabolite signal amplitude are normally calibrated against a reference signal of known
metabolite concentration, generally via use of a phantom.33,48
Types of MRS
Two distinct methodologies of performing spectroscopic examination exist:
single-voxel and multi-voxel spectroscopy.22,33
Single-voxel spectroscopy (SVS)
With single-voxel spectroscopy (SVS), a single sample obtained from a onedimensional volume, with a typical measurement of approximately ≥ 1 cm3, is placed
over a region of interest (ROI). The spectral data are then obtained from that single-voxel
using point resolved spectroscopy (PRESS) or stimulated echo acquisition mode
(STEAM) acquisition modes.33,45 Single-voxel spectroscopy can generally be performed
with faster scan times as compared to multi-voxel spectroscopy.45 Additional advantages
of SVS include minimal lipid contamination, improved magnetic field homogeneity, and
improved water suppression.45,49 Placement of the voxel in single-voxel spectroscopy is
crucial, as slight errors in voxel placement can lead to errors in interpretation of the
spectral data, due to the inclusion of unintentional and undesirable regions of the brain,
bone, gas filled sinuses or adipose tissue.45 Of the two methodologies, SVS results in a
spectrum with a lower signal-to-noise (SNR) ratio.22
Multi-voxel spectroscopy (MVS)
In contrast, multi-voxel spectroscopy (MVS) uses chemical shift imaging (CSI)
acquisition to acquire multi-dimensional spectra from multiple smaller voxels within the
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same volume of tissue, which can be presented as individual spectra.33,45 Multi-voxel
spectroscopy allows for the placement of smaller voxels within the tissue and can be used
to acquire spectra from multiple locations.49 Multi-voxel spectroscopy, however,
typically requires longer acquisition time to perform when compared to single-voxel
spectroscopy and, due to its use of CSI, is more susceptible to contamination from
adjacent voxels, notably air, bone, and adipose tissue. The SNR, however. is generally
higher for MVS.45
Comparison of MVS and SVS
Despite the variation of the two methods, few studies exist comparing results
garnered.22,50 No studies exist in the medical or veterinary fields that statistically compare
the metabolite concentrations and or ratios generated from these two methodologies in
vivo in the clinical setting.
Clinical use of MRS in people
Clinical and research applications of MR spectroscopy are well described in the
medical literature. A large body of literature exists regarding specific metabolites and
their concentrations with regard to the human brain and numerous disease processes
afflicting central neuronal tissue.30,31,34,45,51-53 Clinical applications have been described
for multiple other tissues such as the prostate and breast.30,45 In people, MRS has been
shown to be clinically valuable in the characterization of various brain lesions, including
neoplastic, infectious, inflammatory lesions, as well as traumatic brain injury.30,31,36,54-60
In contrast, the veterinary literature is limited to short descriptive pilot studies and limited
clinical applications of MRS.37,38,49,50,61
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Proliferation of the number of publications regarding MR spectroscopy
Publications regarding MR spectroscopy (blue), and its clinical (red) applications and
pre-clinical (yellow) applications. Notice the increase in total papers until the 1990s, and
the relative plateau from 1990–2010. Adapted from Rosario Lopez, University of
Glasgow, The future of MRS, 2010.
Over the past 3 decades, the popularity of spectroscopy increased and then
plateaued. Limited reviews and the multiple factors that contributed to the rise and
decline of the clinical utility of MRS’s frequent uses are discussed below. Meta-analyses
of MRS techniques and applicability, especially when combined with conventional MR
imaging, have clinical value in aiding physicians in the task of differentiating various
disease states in people. When using MRS for the diagnosis of prostatic cancer, in one
meta-analysis of 31 reports, dating from 1998 to 2008, the sensitivity and specificity
(when combined with conventional MR images) were high (on the order of 75–95%) and
reported to be as high as 100% in some studies.62 A separate meta-analysis, which
included 19 studies ranging from 1998 to January 2012, showed similar results when
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using spectroscopy for distinguishing benign versus malignant breast nodules. When
combined with MRI, the pooled sensitivity in this analysis was 73%, whereas the pooled
specificity was 88%.63 A meta-analysis of hepatic changes in people, which included 46
articles ranging from 1983 to 2009, found a sensitivity of 72.7%–88.5% when using MRS
alone, which was similar to both ultrasound and CT and less than that of MRI alone.
However, the specificity of MRS was 92.0%–95.7%, which was higher than that for
ultrasound, CT, or MRI (for which the sensitivity was 82% and specificity was 89.9%).64
A meta-analysis of brain disease, including 24 studies ranging from 1995–2013, found
that MRS has a sensitivity of 80.05% and a specificity of 78.46% when imaging brain
tumors in people.65 It was also concluded that in general over the studies in the analysis,
MRS performed better, with higher sensitivity and specificity, than conventional MRI for
diagnosing brain tumors.65 Finally, MRS has clinical value even in brain states which
lack morphologic lesions on conventional MR imaging or macroscopic evidence of
disease such as epilepsy and schizophrenia.66 When looking at changes associated with
schizophrenia in people, an analysis of 64 papers found that there was a perceptible
decrease in NAA in various tissues in the brains of affected patients.66 However, these
same meta-analyses also found numerous discrepancies between reports. For instance,
when imaging patients with prostate cancer, specificity was reported to be as low as 33%,
while the sensitivity was reported to be as low as 14%.62 These conflicting reports are
only a part of the reason why MRS is not currently widely used clinically.
The units in which MRS data are reported are arbitrary and proprietary based on
the software used for acquisition.4 In principle, all spectra obtained by MRS can be used
to derive absolute concentrations via the following equation:
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[𝑴] = [𝑹]

𝑺𝑴
𝑺𝑹

𝑪𝑴𝑹

(2.3)

where [𝑀] is the metabolite concentration, [𝑅] is a calibration reference of known
concentration, 𝑆𝑀 is the detected signal from the metabolite, 𝑆𝑅 is the detected signal
from the known reference, and 𝐶𝑀𝑅 is a correction factor which accounts for differences
in relaxation times for T1 and T2, diffusion, the gyromagnetic ratio, magnetic
susceptibility, and generally any other differences between the reference compound and
the metabolite.4 These factors can be different with different proprietary software
packages. Understandably, the calculation of a reliable correction factor (𝐶𝑀𝑅 ) is
challenging and can be time consuming.4 Instead, ratios of metabolites (for instance,
NAA/Cr) are use when making comparisons across different systems.4 However, care
must be taken when interpreting ratios, as changes in ratios may be due to one of many
different factors.4 For instance, if Cho/Cr increases, it may be due to 1) an increase in the
Cho concentration, 2) a decrease in the Cr concentration, 3) a change in both Cho and Cr,
or 4) a change in relaxation parameters for either or both metabolites.4 Thus, patterns of
recognition should be interpreted with conventional images, post gadolinium-based
chelated agents (GBCA) enhancement patterns and the clinical presenting picture.
Further, ratio changes do not indicate the degree of change in either metabolite if both
metabolites are abnormal.
MRS is not currently widely clinically available. There are numerous reasons for
this lack of availability. The aforementioned discrepancies between historical studies of
MRS have called into question its value as a clinical tool, and the proprietary nature of
the units makes it difficult to draw meaningful conclusions between systems.
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Additionally, there are no accepted, standardized clinical techniques for performing
MRS. For example, tumor evaluation comparing the periphery or center of the tumor can
yield varying profiles such that even comparisons across the same tumor type may vary
significantly, lending further credence to the notion that patients are best served by
interpreting MRS in concert with the total clinical picture (Jennifer Gambino, personal
communication, March 2, 2015). Partly as a result of these multiple factors, insurance
companies do not cover spectroscopy as a clinical test. Partially as a result of this, there is
reluctance to accept its clinical and the test is not generally available (Michael Garwood
via Jennifer Gambino, personal communication, March 1, 2012). As a result of this
unavailability, the majority of the data available concerning MRS is from clinical studies
and research.4
Veterinary use of MRS
The available veterinary literature supports the feasibility of MRS as an imaging
technique for the canine brain.37,38,49,50,61 Previous veterinary studies have reported
metabolite concentrations in the brains of both healthy and diseased tissues in dogs using
both SVS and MVS.37,49 Normal concentrations of N-acetyl aspartate, choline, creatine,
myo-inositol, glutamine-glutamate complex, and glutathione in the basal ganglia,
thalamus, parietal lobe, occipital lobe, and cerebellum in healthy dogs at 3T are described
using SVS.49 However, few studies exist reporting metabolite concentrations obtained via
MVS in the normal canine brain.49 Additionally, no data exists regarding MVS
concentrations in the parietal lobe of the normal canine brain. MRS concentrations in
additional tissues, including the prostate and abdominal organs, are not described.
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Table 1.8

Lobe of

Mean metabolite ratios in normal dogs in vivo at 3 Tesla using single-voxel
spectroscopy
NAA/Cr

Cho/Cr

Glx/Cr

mI/Cr

Glutathione/Cr

1.01

0.31

1.875

1.035

0.265

Thalamus

1.235

0.36

1.80

1.17

0.305

Parietal

1.275

0.315

2.01

1.295

0.30

1.04

0.27

1.78

1.26

0.31

0.98

0.29

1.78

1.53

0.32

brain
Basal
ganglia

lobe
Occipital
lobe
Cerebellum

Data from Carrera at al49
In clinical veterinary use, at 3 Tesla, multi-voxel MR spectroscopy has the ability
to distinguish between neoplastic and inflammatory processes in the canine brain.37,67 In a
clinical, prospective population of 33 dogs with intracranial disease, MRS (specifically a
the N-acetyl aspartate to choline ratio) was 82.7% accurate at differentiating neoplastic
and inflammatory (meningoencephalitides of unknown etiology) intracranial disease
processes.37 In addition, MRS has the ability to distinguish normal dogs from those with
spontaneous hepatic encephalopathy due to portosystemic shunting.38 Relevant spectral
changes in dogs with hepatic encephalopathy included diminished concentrations of
glutamine and glutamate, myo-inositol, choline, and N-acetyl aspartate. Additionally,
single-voxel MRS can distinguish between dogs with tick-borne encephalitis and normal
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dogs.67 Relevant changes in the affected dogs included mild decreases in NAA and Cr,
and a mild increase Glx.67 MR spectroscopy has also been performed in a Toggenburger
goat with a cerebral abscess.44 The spectral changes included increases in succinate,
acetate, lipids, and amino acids, as well as a mild increase in lactate. Both Cho and NAA
were decreased.44 Despite not having normal values for this species, clinicians were able
to distinguish this as an abscess based on the characteristic increase in succinate, acetate,
and amino acids.44 Normal MRS concentrations have been reported in non-human
primate species, but not in any additional animal populations.
Additional ex vivo studies in animals also exist. An ex vivo study using MRS
investigating the spectroscopic differences between normal, reactive, and metastatic
lymph nodes found that the Cho SNR was significantly higher for metastatic lymph
nodes compared to both reactive and normal nodes.68 However, no differences were seen
in the Cho SNR between reactive and normal lymph nodes.68 Unfortunately, the
veterinary radiology department at that institution no longer exists. This is a feature not
unique to veterinary institutions across North America, given the unilateral migration of
veterinary radiologists to the private sector. Although there is a growing body of
literature describing metabolite concentrations and ratios in the normal dog (especially
with multi-voxel spectroscopy), gaps in the veterinary literature remain and are subject to
such dilemmas. Further, no studies in the literature exist comparing the clinical utility of
SVS and MVS in vivo in companion animals. The paucity of literature becomes
especially important in situations where time is of the essence (as all animal clinical
patients are under general anesthesia when undergoing MRI) and, in some cases where
magnet throughput for human patients takes precedence over that of companion animals.
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The dog is a historically viable translational model for brain physiology and
disease states. Concerning the research topics discussed herein, improvements in the
body of knowledge of advanced MRI techniques (or ancillary techniques exclusive of
conventional MR imaging) such as MRS; and evaluating GBCA use, administration and
tissue deposition in the brains of healthy dogs, not only advances knowledge for the
veterinary clinician, but provides a translational platform for expanding knowledge for
medical practitioners.69,70
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CHAPTER II
COMPARISON OF SINGLE- AND MULTI-VOXEL SPECTROSCOPY IN THE
NORMAL CANINE BRAIN AT 3 TESLA
Study purpose
The purpose of this portion of the study is to prospectively evaluate the validity of
raw data single-voxel MRS compared to post-processed multi-voxel MRS in the normal
canine brain at 3 Tesla in the parietal lobe, thalamus, and piriform lobe, to determine if
metabolite concentrations and ratios obtained by these two methodologies are statistically
different, and to describe for the first time the normal multi-voxel metabolite
concentrations and compare the ratios and quality of data obtained by both techniques for
each of the described brain lobes.
An additional purpose of this study was to add to the available veterinary
literature regarding metabolite concentrations in the brains of normal dogs using both
SVS and MVS. Specifically, MVS metabolite concentrations have not previously been
reported in the piriform lobe in dogs. Additionally, no studies exist comparing in vivo
SVS and MVS results in the veterinary population. One aim of this study was to provide
this comparison. SVS is easier, and in most cases faster, to perform when compared to
MVS. At some institutions, as is the case at the author’s institution, limited time for use
of the magnet may influence the ability to perform MVS. In addition, post-processing
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software availability, upgrade costs, and the complexity of use even of freeware, may
also limit the clinical utility of MRS at some institutions.
Hypothesis
The author and cohorts hypothesized that although performed using different
acquisition techniques, single- and multi-voxel spectroscopy would yield comparable
spectra and metabolite ratios, with a lack of a statistically significant difference between
the two methodologies.
Methods and materials
Design and execution of in vivo portions of this study and subsequent surgical
laboratories, were subject to institutional review board oversight (Institutional Animal
Care Use Committee protocol numbers 15012, 12065, and 15075). Financial support was
provided by Dr. Gambino through the Department of Clinical Sciences and by the
American College of Veterinary Radiology. In addition, Dr. Gambino provided direction
and had oversight over all aspects of the current study concept, design, drafting, revision,
final approval and had full control of the acquisition, analysis, and interpretation of all
data.
Study population
This prospective, pilot, study population consisted of 8 healthy juvenile purposebred hound dogs. Ages ranged from 5 to 13 months (mean=8.6 months, IQR=5 months).
Two dogs were intact males, five were intact females, and one was a spayed female.
Weights ranged from 17.3–24.8kg (mean=23.76 kg, IQR=8.65). Dogs were deemed
normal based on physical and neurophysical examination performed by a first year
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radiology resident, laboratory animal veterinarian, and a board-certified neurologist.
Complete blood count, serum biochemistry, serum occult heartworm, and serum titers for
Ehrlichia canis, Rickettsia rickettsii, Borellia burgdorferi, and Babesia canis (ProtaTek
Reference Laboratory, Mesa AZ) were performed. All study subjects underwent CT scout
scanning with a 64 detector helical CT (Lightspeed VCT 64-slice, GE Healthcare,
Milwaukee, WI) scanner as a whole body metal (implanted or ingested) screening prior to
MRI of the brain. Following MRI examination in all dogs, all subjects underwent
cerebrospinal fluid aspiration and analysis for cytology and West Nile virus titer testing
(Diagnostic Center for Population and Animal Health, Lansing MI). Further exclusion
criteria for subject selection were not applied.
Technical information: conventional MRI imaging
A daily quality assurance for functional magnetic resonance imaging (fMRI) was
performed the morning prior to all MRI and MRS scanning, consisting of a base echo
planar imaging (EPI) sequence on a phantom. In addition, a week or less prior to all
scans, an American College of Radiology (ACR) phantom scan was performed, the
results from which are evaluated yearly by a licensed medical physicist. Additionally, a
week prior to all MRS scans, calibration was performed for the spectroscopy using a
probe-P phantom (MI385AM, IC6 Medical Advances).
All dogs were sedated with acepromazine (0.01 mg/kg, PromAce, Fort Dodge
Animal Health, Overland Park, KS) and hydromorphone (0.1 mg/kg, Dilaudid, WestWard, Eatontown, NJ) intramuscularly. Animals were induced with propofol (2.3 mg/kg,
PropoFlo, Abbot Animal Health, Abbott Park, IL) and were maintained on an admixture
of isoflurane (Attane, Piramal Healthcare, Bethlehem, PA) inhalant anesthesia and
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oxygen according to a standard clinical protocol and under supervision of the institutional
anesthesia service. Conventional morphologic MR was performed with a 3T magnet
(Signa 3T Excite, General Electric Healthcare, Milwaukee, WI). All animals were
scanned in sternal recumbency with a quadrature knee coil (M1385AM, IGC
[Intermagnetics General Corporation], Latham, NY). A typical clinical conventional MR
imaging protocol was performed in multiple image planes to include: sagittal T1weighted (T1-W) fluid-attenuating inversion recovery (FLAIR); dorsal T2-weighted (T2W); sagittal and transverse T1-W fast spoiled gradient echo (FSPGR); transverse T2-W
FLAIR, T2* fast gradient echo (FGRE), transverse diffusion tensor (DTI); transverse
diffusion weighted imaging with apparent diffusion coefficient mapping (DWI, ADC);
transverse time of flight (TOF) imaging; and a 3-D reconstructable, transverse T1-W
FSPGR series following the intravenous administration of a gadolinium chelated contrast
agent, gadodiamide (Omiscan, 0.5 mmol/mL, General Electric Healthcare, Milwaukee,
WI). As part of a separate study, dogs were administered variable, fractional doses of the
contrast agent as follows: 0.1 mmol/kg (n=2), 0.05 mmol/kg (n=2), 0.025 mmol/kg (n=1),
0.0125 mmol/kg (n=1), and 0.006 mmol/kg (n=1), via the right cephalic vein. Following
intravenous contrast administration, intravenous fluids (0.9% sodium chloride, Baxter
Healthcare, Deerfield IL), at a standard anesthetic flow rate dose of 5 mL/kg/hr, were
administered. Morphologic images were reviewed by a board-certified radiologist and a
second year imaging resident. Animals were included only if morphologic MR brain
images were normal.
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MR spectroscopy
Calibration for the single-voxel spectroscopy was performed using a Probe-P
phantom with known concentrations of metabolites to ensure accuracy of the spectra.

MR Spectroscopy calibration obtained via a Probe-P phantom
Spectrum obtained from a Probe-P phantom demonstrating proper calibration for 3T MRI
prior to spectroscopic imaging. This calibration was performed weekly prior to all
spectroscopic imaging in the study.
Following the acquisition of conventional morphologic brain MR images, singleand multi-voxel spectroscopy was performed on all dogs in one of each of the following
brain regions: parietal lobe (n=3), thalamus (n=2), and piriform lobe (n=3).
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Prior to spectroscopic imaging, third order shimming was performed to correct for
any inhomogeneity in the magnetic field. Water suppression was additionally performed
in order to acquire spectra for the required metabolites. Full width at half maximum
(FWHM) smoothing was performed as a measurement of the width of the signal and to
improve magnet homogeneity and optimize the signal-to-noise (SNR) ratio for the
spectra. Maximum FWHM value for the spectroscopic study was 8 Hz. Animals were
included only if the FWHM value was less than 12 MHz.

Single-voxel and multi-voxel magnetic resonance spectral examples
Spectra from the thalamus of a neurologically normal dog with normal brain morphology.
Spectrum from each of the two described. A– Resultant single-voxel acquisition from the
right hemisphere and B– Resultant multi-voxel acquisition.
For consistency for single-voxel acquisition, a single rectangular ROI was placed
in the left hemisphere at the following locations: parietal lobe (3 dogs), thalamus (2
dogs), and piriform lobe (2 dogs), using the transverse T2-W images for localization. The
dimensions of this voxel were recorded and an identical voxel was created and used for
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the multi-voxel spectroscopy on the same lobe in the contralateral (right) hemisphere
(Figure 2.3). All voxels were placed by a licensed MRI technologist under the
supervision of a board-certified radiologist, board-certified neurologist, and/or second
year radiology resident once protocol was established.
For multi-voxel acquisition, the transverse T2-W images were again used for
localization purposes. A voxel ROI with identical dimensions to the ROI used for singlevoxel acquisition was placed in the right hemisphere in the same region of the brain as
the SVS acquisitions: parietal lobe (3 dogs), thalamus (2 dogs), and piriform lobe (3
dogs). Following removal of the animal from the magnet, post-processing of two smaller
ROIs from the larger, rectangular MVS acquisition were performed. Briefly, a smaller, 5
mm square voxel ROI and a 5 mm diameter circular ROI within this original larger MVS
ROI were interrogated (Figure 2.3).

40

Single-voxel and multi-voxel spectroscopic region of interest (voxel
localization)
A– Single-voxel and B– multi-voxel spectroscopic voxel placements within the thalamus
of a morphologically normal canine brain. In B, notice the smaller green spectrum within
the larger localization, giving a read out for that specific localization such that multiple
regions within a given interrogation can be evaluated.
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Post-processed multi-voxel regions of interest
Post-processed multi-voxel regions of interest created from the same multi-voxel
spectroscopic voxel in Figure 2.3. A– Small square, and B– small circular region of
interest. Each has a width (or with a diameter) of 5 mm respectively. These smaller
regions were created following removal of the subject from the magnet bore at the
console for comparison to the two original larger voxels and the single-voxel spectral
acquisition from a region of interest placed in the same region within the contralateral
hemisphere.
Details of post-contrast single- and multi-voxel acquisition parameters are given
below in Table 2.1.
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Table 2.1

MR spectroscopy acquisition parameters for single-voxel and multi-voxel
studies

Parameter

Single-voxel

Multi-voxel

TR (ms)

1500

1500

TE (ms)

30

30

NEX

16

4

Flip angle

90o

90o

Echo train

1

1

Echo number

1

1

Spectroscopic matrix

1x1

18x18

Cerebrospinal fluid analysis
Following conventional morphologic and spectroscopic imaging, all dogs
underwent cisternal cerebrospinal fluid centesis by a board-certified veterinary
neurologist (MB) during the immediate imaging recovery phase. All dogs then received
subcutaneous carprofen (4 mg/kg, Rimadyl, Zoetis, Florham Park, NJ) and were
recovered from anesthesia uneventfully. Only dogs meeting the criteria of cerebrospinal
fluid (CSF) analysis results within normal reference ranges, with no evidence of
xanthochromia, infectious organisms or abnormal cellular concentrations, and negative
CSF titers for West Nile Virus were included.
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Histopathology
Following imaging and recovery, all dogs were surrendered to an unrelated nonimaging terminal surgical laboratory. Upon completion of that study, animals were
euthanized. The brains of each of the subjects were harvested no more than four hours
following euthanasia. Brains were stored in formalin and fixed neurologic tissue from
each of the evaluated lobes was submitted for histopathologic evaluation to confirm the
normal status of the tissue. All dogs met the inclusion criteria of having normal gross and
histopathologic brain evaluation by a board-certified pathologist in the frontal, parietal,
and piriform lobes, thalamus, cerebellum, brainstem, motor cortex, and hippocampus.
Data analysis and post-processing
SVS spectra resulted in data processed in MACH values (arbitrary machine units)
according to the inherent post-processing algorithm for NAA, Cho, Cr, MI, and H20.
Additionally, MACH values for each individual ppm along the horizontal axis of the
spectra were obtained. MVS spectra were evaluated in both relative (to water) and
absolute concentrations according to the inherent post-processing algorithm (Func Tool,
FuncTool Performance, General Electric Healthcare, Milwaukee, WI) for NAA, Cho, Cr,
mI, Lip, Lac, Ala, and Tau. Concentrations were evaluated for all methods of MVS
acquisition (large SVS-like rectangular ROI, smaller square within lobe of interest and
circular ROI.
Prior to metabolite evaluation, baseline water and lipid correction post-processing
were applied to the MVS data sets. Metabolite peaks for NAA, Cr, Cho, and mI were
obtained from via automated processing with FuncTool. NAA, Cr, Cho, mI, Lac, Lip, and
Tau peaks were obtained for all three regions of interest utilized during multi-voxel
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spectroscopy. Absolute values, as well as relative values, for these peaks were archived
for the multi-voxel spectroscopy technique.
Statistics
All statistical analyses were performed by an epidemiologist/statistician. A mixed
model analysis was conducted using PROC MIXED in SAS for Windows v9.4 (SAS
Institutes Inc., Cary, NC). For each metabolite measured, a model was fit with fixed
effects of lobe imaged and technique used (SVS vs MVS). Dog identity was included as a
random effect with a compound symmetry covariance structure. Differences in least
squares means (lsmeans) with Tukey-Kramer adjustment for multiple comparisons were
determined for outcomes with a significance fixed effect. An alpha level of 0.05 was used
to determine statistical significance for all methods. All data were normally distributed.
Mean metabolite values were obtained for both single-voxel and post-processed
multi-voxel techniques in all three imaged regions of the brain (Tables 2.4 and 2.5).
Ratios for each of the methodologies (single- and multi-voxel) were compared (Table
2.6). The following ratios were compared: Cho/Cr, Cho/NAA, NAA/Cho, NAA/Cr,
Cr/Cho, and mI/Cr. Calculation of ratios was performed to compare the peaks of the
spectra from both single- and multi-voxel techniques without needing to convert the
MACH numbers of the single-voxel spectroscopy to the relative or absolute part per
million results of the multi-voxel spectroscopy.
Results
Conventional and advanced MRI examinations were successfully performed in all
dogs and deemed normal by a board-certified veterinary radiologist, 2nd year imaging
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resident and board-certified veterinary neurologist. Advanced protocols demonstrated
normal brain diffusion and perfusion. A total of 6/8 dogs had successful spectroscopy
performed bihemispherically and these spectra were deemed normal based on historically
available comparisons in the available canine literature.49,50 All images were of excellent
diagnostic quality and none were excluded from the image scoring. No complications
were observed in any dog secondary to the phlebotomy, gadolinium chelated contrast
administration, MRI examinations or cisternal cerebrospinal fluid centesis. All
hepatorenal values were normal in all dogs, as given in Table 2.3. Infectious disease titers
for Ehrlichia canis, Rickettsia rickettsii, Borellia burgdorferi, and Babesia canis were
negative, all dogs tested heartworm negative, and CSF analyses and cytology results were
unremarkable (protein quantification <30 mg/dL with nucleated < 5 cells/uL) in all
animals. All animals recovered uneventfully from anesthesia.
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Table 2.2

Hepatobiliary and renal serum biochemistry values for all dogs.

Subject

Alk Phos

number

U/L
(reference

ALT U/L
(reference
range 10–90

range 11–140

T Bili mg/dl
(reference range
0.2–0.6 mg/dL)

BUN mg/dl

Creat mg/dl

(reference range

(reference range

8–24 mg/dL)

0.5–1.4 mg/dL)

U/L)

U/L)

1

120

12

0.6

9

0.6

2

130

10

0.3

8

0.8

3

138

13

0.2

8

0.6

6

135

16

0.3

12

0.81

4

86

28

0.4

9

0.87

7

73

36

0.3

10

0.78

5

92

27

0.3

10

0.14

8

90

34

0.2

8

0.76

All dogs had normal hepatobiliary and renal values.
Metabolite concentrations
Two spectra were excluded from the study. The parietal voxel in dog 1 was
excluded due to suboptimal voxel ROI placement. The piriform voxel ROI placement in
dog 6 was also excluded, as the voxel was too small, and the resultant spectral data were
non-diagnostic due to a high signal-to-noise ratio. In the remaining 6 dogs, diagnostic,
quality spectra were obtained in the thalamus (n=2), parietal lobe (n=2), and piriform
lobe (n=2).
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Table 2.3

Mean brain metabolite concentrations, given in machine (MACH) units,
acquired using single-voxel spectroscopy in the thalamus, parietal lobe, and
piriform lobe of six dogs

Metabolite

Thalamus

Parietal lobe

Piriform lobe

(n=2)

(n=2)

(n=2)

NAA

21

25.5

20

Cr

14.5

17.5

14

Cho

18.5

18

16.5

mI

11

13

13

H20

22383.5

27353

21890

48

Table 2.4

Metabolite

Mean brain metabolite concentrations, given in absolute ppm units,
acquired using multi-voxel spectroscopy in the thalamus, parietal lobe, and
piriform lobe of six dogs.
Thalamus

Parietal lobe

Piriform lobe

(n=2)

(n=2)

(n=2)

NAA

2175

2227.167

1780

Cr

1404

1396.5

918.167

Cho

1624

1440

1499.167

mI

1091

1389.833

1465.333

Ala

8.3

96.4

43.133

Lac

459

340.667

506.222

Lip

508

345

575.167

Glx

1014.9

1264.34

813.306

Tau

458.147

517.235

186.709

Single-voxel spectroscopy was compared for the three sampled lobes of the brain
for the following metabolites: NAA, Cho, Cr, and mI. Water was also included in this
analysis. The large, SVS-like rectangle, small square, and small circle post-processed
MVS voxels were compared for the following metabolites: NAA, Cho, Cr, mI, Lac, Lip,
Glx, Ala, and Tau. Metabolite ratios were compared for SVS and the three post-processed
MVS voxels. The specific ratios compared were: Cho/Cr, Cho/NAA, NAA/Cho,
NAA/Cr, Cr/Cho, and mI/Cr.
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Table 2.5

Ratio

Metabolite ratios given for both single-voxel and multi-voxel spectroscopy
performed in the thalamic, parietal, and piriform lobes of the brains of six
dogs.
Thalamus

Parietal lobe

Piriform lobe

(n=2)

(n=2)

(n=2)

SVS

MVS

SVS

MVS

SVS

MVS

Cho/Cr

1.27

1.16

1.03

1.01

1.21

1.62

Cho/NAA

0.88

0.75

0.71

0.63

0.83

0.85

NAA/Cho

1.14

1.34

1.41

1.63

1.22

1.19

NAA/Cr

1.45

1.55

1.46

1.62

1.45

1.92

Cr/NAA

0.69

0.65

0.69

0.62

0.70

0.53

mI/Cr

0.75

0.76

0.74

0.98

0.95

1.58

Comparison of SVS and MVS
In line with the proposed hypothesis, statistically significant differences were not
seen between SVS and the identically sized (large rectangular) MVS acquisitions for any
given lobe. In addition, when comparing the MVS acquisitions, no statistically significant
differences were found between the larger rectangular MVS acquisitions and either the
small circle or the small square MVS ROIs.
For Cr/NAA, statistically significant differences were seen between the (large)
SVS ROI, and the smaller, post-processed MVS ROIs (the small square and SVS
(p=0.0442); and the small MVS post-processed circle and SVS (p=0.0223). Finally, for
NAA/Cr, a statistically significant difference was seen between the SVS and the smaller,
post-processed MVS circle (p=0.0456).
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Irrespective of technique, no significant differences in regional concentrations
were seen between the thalamus and parietal lobe for any metabolite or ratio. Statistically
significant differences were, however, seen for Cho/Cr between the piriform and the
parietal lobes (p=0.002) and between the piriform lobe and the thalamus (p=0.0067). For
mI/Cr, statistically significant difference was also seen between the piriform the parietal
lobes (p=0.0281) and between the piriform lobe and the thalamus (p=0.0047).
Discussion
Both single- and multi-voxel spectroscopy were successfully performed in 6/8
dogs in this study, with no adverse effects from the spectroscopic procedures, contrast
administration, or CSF centesis observed. In addition, metabolite concentrations were
successfully obtained for both SVS (MACH units) and MVS (parts per million) in all
three interrogated regions of the brain (Tables 2.4 and 2.5). There are a few reports that
describe normal regional SVS and MVS concentrations in dogs; however, this study is
the first to compare SVS and MVS ratios in a normal, juvenile dog population.
Collectively, the results of the current study provide clinicians with the regional
concentrations of metabolites for the sections investigated for which the previous
literature is sparse or non-existent. An objective baseline quantification of the metabolite
reference values in the normal juvenile canine brain (for the thalamus, parietal lobe, and
piriform lobes), included herein provides veterinarians interpreting MR brain spectra a
measurable parameter allowing for future comparison to various disease states.
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Differences between SVS and MVS
No significant differences were detected between the bihemispheric metabolite
ratios obtained by way of the two different spectroscopic methodologies (SVS versus
MVS) when using identically sized and shaped, rectangular ROIs. In addition, no
significant difference was seen between the smaller ROIs (both the rectangular and
circular), and the large rectangular MVS ROI. However, differences were seen for some
ratios obtained by way of SVS when compared to the smaller (rectangular and the
circular) MVS ROIs. These differences were attributed to signal volume averaging across
the entire SVS ROI, which can be dramatic in SVS acquisition data sets, versus more
manipulable for a given MVS ROI. Signals furthest from the center of the given SVS
ROI contribute to decreased SNR and a greater amount of signal degradation.33 This
finding is due to an averaging of the signal coming from the periphery of the ROI, where
the signal to noise ratio is lower.33 Thus, in general (for both techniques), the larger a
given ROI, the greater the degree of contamination of the final, resultant spectrum by
degraded signals coming from the periphery of the ROI. This peripheral signal
degradation and sample averaging are the likely reasons that comparing the SVS
acquisition to the smaller MVS acquisitions, which were obtained from a central region
within the large (rectangular, SVS-like) MVS acquisition, resulted in significantly
different values for a limited number of ratios and metabolites. The raw SVS data set was
a large volume that included the peripheral signal degradation, whereas the smaller MVS
acquisitions excluded the areas of poor signal and only included the strongest
contributing signals in addition to eddy current and lipid and water baseline correction
post-processing. In addition, smaller voxels are more easily placed in the tissue of
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interest, minimizing contamination from other regions of the brain. This may prove to be
especially important in clinical patients, where lesions may be smaller than the initial
large volume, and only those voxels over the lesion would need to be selected for the
post-processing. It is possible and likely that, had we post-processed our single-voxel
data, and diminished the effect of the averaged peripheral signal, using MRS postprocessing software (for example, LCModela), we likely would have not seen any
significant difference between these ratios. However, we decided to compare raw-data
SVS to post-processed MVS as this would mimic the clinical situation at our institution.
Despite the availability of MRS freeware (such as Tarquinb, SIVICc, and jMURId), the
author decided to test the current limitations of the scanner that does not include the
software package to allow for post-processing of the SVS data set. Regardless, results
from the study indicate that, when the same volume of tissue interrogated (same in size
and shape), from the same region of brain, there is no statistically significant difference
between raw data SVS and post-processed MVS methodologies. Although the removal of
eddy current and lipid contamination is desirable for obtaining a “perfect” spectra from
an ROI, it may not offer a perceptible clinical difference, and it is this point that is
contrary to previous literature that claims that SVS was not as clinically useful as MVS.50
Although there is no argument that MVS is a more robust test, results of the current study
support the use of raw data SVS and ratios as a clinically relevant test for institutions that
have similar software limitations. When using the same volume ROI, the results between
SVS and MVS are not statistically different. This point brings into question the risks and
benefits of choosing SVS (a shorter, albeit less perfect) acquisition protocol over MVS in
the clinical setting when time is of the essence (especially true in veterinary MR imaging,
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given that patients are anesthetized for the duration of the scan). In addition, results from
this study support the notion that data (specifically ratios) garnered from different
institutions using different spectroscopic methodologies and proprietary software, can be
compared and/or compiled for future work and disease metabolite profile banking,
allowing for a greater number of spectroscopic collaborations given the need for larger
cohort studies in clinical patients with brain disease states.
Concerning the regional concentrations and the difference noted, irrespective of
technique, differences were detected between the piriform and parietal lobes and the
piriform lobe and the thalamus for Cho/Cr. A statistically significant difference was also
seen between the piriform and parietal lobes, and between the piriform lobe and the
thalamus for mI/Cr. This difference between lobes is similar to prior studies for both
humans and dogs, which reported differences in metabolite concentrations in various
lobes of the brain.49,71 A previous canine study reported differences in NAA, Cho, Cr, and
mI for the following regions: basal ganglia, thalamus, parietal lobe, occipital lobe, and
cerebellum.49 In addition, we did not find a difference between the parietal lobe and the
thalamus, which is in contrast to a prior study in dogs.49 There are several possible
reasons for this discrepancy. The placement of our voxels in these regions may have been
slightly different than previous reports due to a human estimating the relative ROI and
due to differences in the exact size of the ROI placed upon these regions, which is a well
described caveat to voxel placement for spectroscopic evaluation in that repeatability is
often difficult with regard to precision. Furthermore, although unlikely, we cannot
definitively rule out that none of the samples in our, or in previously reported studies
were completely free of lipid contaminant. The difference may also be attributable to the
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low numbers of dogs and comparative voxel placements for each of the regions
interrogated in our study.
Comparison to prior studies
There is an abundance of research and clinical spectroscopic data in people that
has, over the past three decades, enhanced the sensitivity and specificity of conventional
brain imaging.25-28 As previously stated, MR sensitivity in the brain is reported at 95%–
99%, while the specificity is reported to be 70%–76%.25,29,72 The lower specificity is due
to signal overlap in MR imaging characteristics and lesion morphology between various
disease etiologies in the canine brain.26 When spectroscopy is added to conventional MR
imaging, the sensitivity is reported to be 80%–100%, however, the specificity increases
to 78%–100%.30,31 Better pattern recognition, due to a higher number of published cases,
is postulated to be the reason for the increasing specificity in later studies.30
Many of the studies described employ the use of an identical ROI within the
presumed normal, contralateral, hemisphere for comparison.49 Previous studies in both
people and dogs demonstrated only few statistically significant differences between
hemispheres for the same regions of the brain, including the basal ganglia, thalamus,
parietal lobe, occipital lobe, and cerebellum.49,73-75 Specifically, in dogs, mI/Cr differed
between hemispheres in the parietal lobe in dogs.49 Additionally, a small but significant
difference between the two hemispheres for the thalamus is described.49,76,77 By and
large, there were no significant regional differences in this study, within the limited
metabolic profile evaluation, with the only significant differences seen being the Cho/Cr
between the piriform and the parietal lobes (p=0.002) and between the piriform lobe and
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the thalamus (p=0.0067) and for mI/Cr between the piriform the parietal lobes
(p=0.0281) and between the piriform lobe and the thalamus (p=0.0047).
At the author’s institution, when pathologic brain changes are unique to one
hemisphere, an ROI in the contralateral hemisphere at the same location is placed for
internal comparison, allowing the patient to serve as its own control. This is an ideal
practice, given variations of normal affected by age and brain region.35,51,78 The author
chose to perform SVS on one hemisphere and MVS on the other hemisphere because it
reflected what is routinely done in the clinical setting at the author’s institution. Given the
findings of this and previous studies, it is highly unlikely that there is any significant
difference between the two hemispheres for any lobe.49,76,77 However, slight differences
between the lobes may exist, which would confound comparison of spectral data obtained
by way of different protocol methods (namely, SVS and MVS).
The dogs in this study were juvenile, with a mean age of 8.6 months. The results
of this study are similar to results in human pediatric and juvenile patients, where
pertinent findings include low/normal NAA (due to developing neurons and axons),
low/normal Cr, which is believed to be due to glial changes, and relatively normal mI,
Cho, and GLX concentrations, as compared to the adult values.35
Additional experimental considerations
There were a few limitations to the current study. The animals used in this study
were all juvenile, with a mean age of 8.6 months. The juvenile status of the study
population may therefore not be the ideal dataset for which to compare datasets obtained
from geriatric patients. Although the MR evaluation of the maturation of grey and white
matter have been reported to reach adult appearance by 16 weeks of age in dogs,
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spectroscopic differences are reported for metabolite concentrations and ratios throughout
maturation in people; and when comparing between juvenile, adult, and geriatric patients
(in people and dogs).76,77,79-81 In dogs, increases in Cho/Cr are noted in young dogs
compared to adult and geriatric dogs, with the proposed mechanism being increased
myelination in younger animals.80 In addition, NAA to choline is reportedly significantly
lower in young and geriatric dogs compared to adults.80 All animals in our study were of
a similar age. It is likely that the shift from the juvenile to adult spectroscopic
concentrations and ratios occurs at varying ages in dogs and over a period of time, though
likely not entirely analogous to people given the differences in life span. Due to the
narrow age range of the canine subjects evaluated in the current study, it is unlikely that
there would be large enough differences between the animals to significantly affect the
metabolite concentrations and ratios. Furthermore, comparisons made between ROIs of
the SVS and MVS acquisitions were performed in different hemispheres of the same
animal. However, small differences could feasibly affect results. Finally, interspecies
differences (given the wide variety of existing veterinary patient species) are likely to be
encountered such that the dataset presented herein is not intended to be viable for
comparison across species. Further investigation is needed to determine metabolite
concentrations and ratios in a range of ages in dogs and cats.
Different doses of gadolinium contrast agent were administered to these dogs
during the MRI examination as part of a separate study (refer to Chapter IV). The effect
of gadolinium contrast agents and their effect on the resulting spectra have been
investigated. No statistically noted differences for NAA/Cr, Cho/Cr, and NAA/Cho are
noted in patients with intra-axial brain tumors before and after administration of a
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gadolinium contrast agent.82 It is a generally well accepted principle that these agents do
not affect the baseline concentrations of brain metabolite composition.82,83
The current study population included both male and female dogs. Historically,
gender has no significant effect on baseline brain metabolite concentrations. 49,76,77,81 The
authors consider the heterogeneous population adventitious and representative providing
data for both sexes
Limitations
There are several limitations to the study. The most significant limitations are the
low number of study subjects and limited age group evaluated. However, when compared
to the limited available literature there was good correlation with metabolite ratios
suggesting sound methodology. A larger cohort of dogs will be required to confirm these
preliminary/pilot results. Although voxel size was maintained for each lobe of the brain,
placement of the voxels was subject to both human error and slight variations in the
anatomy of the dogs imaged. Additionally, this study used a specific age and breed of
dog. A larger study, incorporating a larger variation in age, breed, and size of dog, may
show differences that were not detected in the current study.
Conclusion
In conclusion, both SVS and MVS were successfully performed on this pilot
study cohort of 6/8 dogs in the thalamus, the piriform lobe, and the parietal lobe. The two
exclusions were due primarily to inconsistencies of exact voxel placement and human
error, an issue not specifically unique to the authors of the current study. This issue has
previously been discussed as a limitation when following brain lesions in the same
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patient over time and is, to date, an unavoidable problem. One spectra was excluded due
to poor placement of the voxel, and one spectra was excluded due to small voxel size,
leading to a low signal-to-noise ratio. There was no statistically significant difference
seen between SVS and large rectangular MVS, although for NAA/Cr and Cr/NAA, a
difference was found between the SVS spectra and the smaller round and square ROI
MVS, again likely due to a number of factors such as signal strength at the center of the
MVS ROI being superior to that of the SVS ROI whose signal is contaminated by that of
the periphery. Differences were seen between the piriform lobe and thalamus and
piriform and parietal lobes for select metabolite ratios. Additional studies, with larger
numbers of dogs, are needed for further exploration and comparison of metabolite ratios
and concentrations in different ages groups of the dog and in other species, such as the
cat, in which MR is routinely performed for clinical and research applications for which
greater diagnostic and baseline MR specificity and sensitivity are warranted.

Footnotes:
a: LCModel, http://s–provencher.com/lcmodel.shtml
b: Tarquin v 4.3.10, http://tarquin.sourceforge.net/
c: SIVIC, https://sourceforge.net/projects/sivic/
d: jMURI, v 6.0, http://www.jmrui.eu/
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CHAPTER III
INTRODUCTION TO MAGNETIC RESONANCE CONTRAST AGENTS
Contrast-enhanced MRI
Gadolinium
History
With respect to the use of MR contrast agents in MR imaging, chemists have
focused their attention fairly uniformly on one element: gadolinium. Gadolinium was first
discovered in 1880 by a Swiss chemist names Jean-Charles Galissard de Marginac via
mass spectroscopy.84 It was isolated in 1886 by the French chemist Paul-Emile Lecoq de
Boisbaudran, who then named it after the Finnish chemist Johann Gadolin.84
Physical properties
Gadolinium is a rare earth, lanthanide series element, with an atomic number (Z)
of 64. It is present at 5 ppm (approximately 6.2 mg/kg), or 100 times the concentration of
iodine, in the earth’s crust.84 It is malleable and forms close-packed crystals at room
temperature.85 At room temperature, gadolinium is paramagnetic but becomes more
ferromagnetic than iron when cooled to temperatures lower than 25 oC.84 The metal is too
reactive to exist naturally, and it adopts the oxidation state +3. The most common halide
encountered is gadolinium (III) chloride, and the oxides can be dissolved in acid to obtain
the separate salts.85 Gadolinium features seven unpaired electrons in its positively
charged ionic form (Gd+3), which is more than any other element.86,87 This molecular
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conformation results in large paramagnetic susceptibility.86,88 Approximately 400 tons of
pure gadolinium are produced each year, and mines exist in the Unites States, China,
Brazil, Sri Lanka, India, and Australia, the majority being for medical use.85
The gadolinium ion, which is a metallic salt, was favored as the active center for
first generation commercial contrast complexes, given multiple favorable physiochemical
properties. These properties include seven unpaired electrons (distributed isotropically in
its 4f shell), which offer an electrically charged magnetic center that exhibits the
strongest effect of all the known elements on T1 relaxation time, its long electronic
relaxation time, and its nine coordination sites.86,87 Gadolinium results in the largest T1
relaxation time of any known element, making it ideal as an MR contrast agent.86
Environmental contamination
In 1996, the first report of gadolinium anomalies in surface waters was
generated.89,90 High concentrations of gadolinium were eventually discovered in several
rivers, lakes, and the North Sea.89 Comparison of the concentration of gadolinium with
other rare earth metals in these waterways showed that gadolinium was the only elevated
rare earth metal. This finding confirmed that the increase in gadolinium was
anthropogenic and due to increased use of gadolinium-based MR contrast agents.89,90
Toxicity
All transition metals exhibit intolerable toxicity.3 Despite favorable properties and
its efficiency as a paramagnetic substance, the Gd+3 aqueous ion is not unique and is
highly toxic to the body.87 It forms acid solutions in water and insoluble hydroxides or
phosphates in solutions of neutral pH, which accumulate rapidly within the
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reticuloendothelial system (RES) following intravenous (IV) administration via
phagocytosis by the Kupffer cells in the liver.86,87 Gadolinium is not as toxic as other
heavy metals like cadmium and lead.91 However, gadolinium has similar biologic and
chemical characteristics (and thus toxicities) to other metals, including cerium, samarium,
and europium.92 In rats and dogs, subchronic toxicity studies demonstrated that
vacuolization of the proximal tubules (osmotic nephrosis) was the most obvious sign of
toxicity in subjects administered up to 5 mmol/kg, daily for 4 weeks.3 Generally, the
osmotic load produced by administration of typically used doses (such as 0.1 mmol/kg) is
considered to be extremely low. Thus, this feature and consideration led to the synthesis
of chelated gadolinium complex, which have reduced osmotic activity.3
In addition, the ionic radius of Gd3+ (107.8 pm) is similar in size to that of Ca2+
(114 pm), and has similar charge. Both of these factors contribute to the ability of the
gadolinium ion to block many voltage gated calcium channels, even at very low
(nanomolar to micromolar) concentrations.84,92 This channel blockage was first described
in the rat atrium in 1994 via blockage of the stretch-activated natriuretic peptide secretion
by gadolinium.93 The free gadolinium ion is neurotoxic. It is known to inhibit
mitochondrial function via nanotube-induced cellular necrosis and DNA damage, and has
been shown to induce oxidative stress in cortical neurons in rats.54,94-98 Although
theoretical for the free gadolinium ion according to some authors,98 with regard to
transition metals in general and oxidative stress, the majority of free radicals generated in
vivo come from transmetallation and the metal catalyzed breakdown of hydrogen
peroxide according to the Fenton reaction:
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Mn+(=Cu+, Fe2+, Ti 3+,Co2+) H2O2M(n+1)(=Cu2+, Fe3+, Ti4+, Co3+)+OH +OH–

(3.1)

where Mn+ is a transition metal ion.98,99 Factors affecting the release of the gadolinium
ion are dependent on metals with high affinity for gadolinium binding ligands such as
copper, zinc, and iron in addition to the presence of ligands that have high affinity for
gadolinium such as phosphorus and carbonate.100 Gadolinium release increases with
decreasing pH. A proposed mechanism for this phenomenon is via uptake of the
gadolinium (in unknown form) into a lysosome containing an inherently low pH such as
occurs within the renal proximal tubules.100
Further, the free gadolinium ion can inhibit muscle contraction, blood
coagulation, nerve impulses, the activity of numerous calcium-dependent enzymes,
including ATPase, kinases, dehydrogenases, and glutathione S-transferases due to its
competition with the Ca2+ ion at various calcium-gated channels and calcium-dependent
enzymes.84,92,94,95 The LD50 for gadolinium chloride (GdCl3), when given to mice and
rats intravenously, is 0.4 to 0.5 mmol/kg, respectively.84,100
Chelation
Chelation complexes can increase safety by a margin of 20 such that toxic effects
are demonstrated only at very high doses, making the LD50 in the range of 8–10
mmol/kg in rats, dogs, rabbits and mice.27 Since tolerance of the gadolinium ion in
laboratory animals was not sufficient to allow clinical studies, detoxification without
altering its inherent paramagnetic properties was achieved by way of coordination
chemistry to various suitable ligands rendering the paramagnetic magnetopharmaceutical
less toxic than the free ion or free organic ligand.87 The chelate, gadolinium
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diethylenetriaminepentacetate (gd-DTPA), was first described in 1984, and successful
clinical experiences in patients were reported later in that same year.101,102 Gd-DTPA,
also known as Magnavist, was FDA approved for clinical use in 1988.103 In order to
mitigate toxicity, manufactured chelates are formed via a chelating process, in which an
electronegative atom donates an electron to the positively charged ion.87 Resultant large
organic molecules form a more stable compound surrounding the gadolinium ion.88,104,105
When ion and ligand are bound together, neither can (in theory and historical belief) react
in vivo to replace physiologic ions (such as calcium), nor can the supramolecular complex
trap other ions (such as zinc).87 Zinc is the second most abundant transition metal in the
body (after iron), with the average human having about 2.3 grams of total zinc in the
body. In theory, zinc is unable to replace gadolinium in the ligand (see equation 3.1).87
Chelation results in a dramatic alteration of pharmacological and toxological properties.87
These gadolinium-based chelated agents (GBCAs) are considered highly soluble in water
at neutral pH, highly concentrated, and hydrophilic, rendering a stable aqueous solution;
this is a general prerequisite for diagnostic agents administered intravenously in small
volumes.87
Beyond the scope of the current discussion, other, non-gadolinium based MR
contrast agents can be used in MR imaging. Magnesium sulfate can be administered
orally for use in MR imaging of the small intestine.106 Calcium (II) and magnesium (III)
ions are both currently being investigated as potential contrast agents.107 Gadoliniumbased chelated agents, however, remain the mainstay of contrast enhanced magnetic
resonance imaging (CEMRI).
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Gadolinium-based chelated agents (GBCAs)
Pathophysiology
The mechanism of action of chelated agents is complex.84 Multiple physical
factors including motion, temperature, viscosity, binding to biomolecules, and
compartmentalization all influence the relaxation rates of bulk water and the relaxivity of
paramagnetic materials.87
When chelated gadolinium is administered intravenously, contrast enhancement
results from the shortening of the T1 and T2 relaxation times of tissues, as the seven
unpaired electrons of Gd+3 match the Larmor frequency, thus increasing the rate of
transfer of energy and decreasing relaxation time.86,88 Unlike typical iodinated
intravenous contrast agents, the contrast effect of GBCAs is indirect. The perceived
hyperintensity on T1-weighted sequences is due to local micromagnetic fields which act
to shorten the T1 relaxation times of the adjacent tissues. Therefore, rather than the
brightness of the image occurring due to the quantity of contrast arriving within vessels at
the tissue bed, as with iodinated or barium contrast agents, the brightness of MR contrast
agent is due to the indirect effect of the agent on the surrounding tissues, not actually
seeing the agent itself in the image.87
The effectiveness of the contrast agent depends greatly on multiple variables. One
of the greatest influencing variables is the applied MR sequence, with the best
enhancement being generated with techniques having the shortest TR and TE such as T1weighted spin echo (with a TR <600 milliseconds and short echo delay time TE less than
40 milliseconds) and gradient echo techniques, provided an adequate pulse angle is
applied.87,88 Contrast enhancement is greater at higher field strengths due to longer
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intrinsic relaxation times of the tissue protons.87,88 Multiple tissue properties/factors
regulate the enhancement ability of a given tissue. Tissues with a large distribution
volume of a paramagnetic contrast agent and long intrinsic relaxation time exhibit the
most significant change in relaxation.87 Therefore, marked enhancement is visible in
lesions with increased extracellular space or areas of increased distribution volume, such
as large accumulations of fluid like within the urinary bladder. Tissues with small
distribution volumes and short intrinsic relaxation times, such as the normal brain, liver
and muscle, do not exhibit a significant increase in signal intensity following the
administration of contrast.87 A third factor regulating the contrast-enhancing ability of the
tissue is the concentration and relaxivity of the agent.87 In vivo, low concentrations of
paramagnetic species are needed to reduce T1 relaxation times, with concentrations as
low as 0.012 mmol L–1 being sufficient to elicit a strong effect on signal intensity.87 In
contrast, T2 relaxation (or susceptibility effect) dominates at very high concentrations
(greater than 5 mmol L–1).87
Administered intravenously, GBCAs have an extracellular concentration
analogous to iodinated radiographic agents with rapid, unchanged renal excretion by way
of glomerular filtration with a half-life of 1–2 hours in people.87 Greater than 90% of an
administered dose can be recovered from the urine 3 hours following intravenous
administration in people.87 Elimination is similar in animals.88,104,108
History of GBCA use
As discussed above, gadolinium-diethylenetriaminepentacetate (gd-DTPA;
gadopentetate, Magnevist), developed in the early 1980s, was the first commercial MR
contrast agent to be approved for clinical use in 1998.87,88 Clinical trials in the early
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1980s demonstrated excellent patient tolerance of gd-DTPA, with adverse drug reactions
being less common than with iodinated radiographic contrast agents. In addition, no
hemodynamic alterations were noted in patients following intravenous administration of
gadopentetate with doses up to 0.3mmol/kg in the first clinical reports.87 Thus, despite of
their lack of specificity, first generation compounds were considered to be safe.87,88
Conspicuity of abnormalities in tissues was determined to be adequate at 0.1–0.2
mmol/kg, and this dose was recommended in many early clinical reports.87 This dose
scheme has continued to current day recommendations.92 There are currently nine FDAapproved GBCAs available in the United States, as provided in Table 3.1. By 1993, over
7 million people had undergone GBCA enhanced MR studies and to date, over 200
million doses have been administered worldwide.87,109,110
Few reports of overdoses of gadolinium exist. A case report from 2010 described
an accidental overdose of 6 mL intrathecal gadopentetate dimeglumine which was
mistaken for an iodine-containing contrast media.111 Clinical signs associated with this
overdose included global aphasia and vomiting; these signs progressed to stupor, rigidity,
and intermittent seizures.111
Types of GBCAs
Within the class of chelated agents, there are four subtypes into which these
agents can be classified. These include the structure of the metalloligand (open-chain vs
macrocyclic) and the charge of the ligand (ionic vs non-ionic). Additionally, GBCAs can
be classified into extracellular or mixed extracellular/organ-specific (hepatocyte) agents.
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Open-chain versus macrocyclic
By structure, GBCAs can be classified into one of two categories. In the openchain or linear classification, the ligand is not fully closed around the gadolinium ion.
This configuration is in contrast to the macrocyclic classification in which the ligand
fully encloses the gadolinium ion; and in which the Gd3+ ion is considered caged within
the pre-organized ligand cavity.84,109 Macrocyclic agents are more stable, with higher
thermodynamic and kinetic stability constants than open-chain agents; this is discussed in
more detail below.

Open-chain vs macrocyclic GBCA structure
Gadolinium based contrast agents can be classified by structure. A–Gd-DTPA
(Magnavist), and its open-chain (or linear) molecular construct and B–Gd-DOTA
(Dotarem), and its macrocyclic molecular construct. Notice the gadolinium ion (green) in
the center of the ligand cavity within the macrocyclic GBCA.
Ionic versus non-ionic
GBCAs can also be organized according to their charge. Ionic agents are charged
after dissociation, while non-ionic agents are neutral after dissociation. While non-ionic
iodinated contrast agents are generally preferred for their safety, ionic GBCAs are more
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stable.87 A list of the FDA-approved GBCAs, as well as their structure and charge, is
provided in Table 3.1 below, as well as in Figure 3.2.
Table 3.2

FDA approved gadolinium based contrast agents

Chemical Name

Trade Name

Manufacturer

Class

Charge

Gadodiamide

Omniscan

GE Healthcare

Linear

Non-ionic

Gadoversetamide

OptiMARK

Mallinckrodt Inc

Linear

Non-ionic

Gadopentetate

Magnevist

Bayer HealthCare

Linear

Ionic

MultiHance

Bracco

Linear

Ionic

Gadoxetic acid

Primovist/

Bayer HealthCare

Linear

Ionic

disodium

Eovist

Gadofosveset

Vasovist/

Lantheus Medical

Linear

Ionic

trisodium

Ablavar

Imaging

Gadoteridol

ProHance

Bracco

Macrocyclic

Non-ionic

Gadobutrol

Gadavist/

Bayer HealthCare

Macrocyclic

Non-ionic

Guerbet

Macrocyclic

Ionic

dimeglumine
Gadobenate
dimeglumine

Gadovist
Gadoterate

Dotarem

meglumine
The compounds in this table are listed in order of least (gadodiamide) to most (gadoterate
meglumine) stable. Adapted from Idee et al 2009.84
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The 9 FDA approved gadolinium-based chelated agents, grouped by their
class and charge.
Linear agents are listed on the right column and macrocyclic agents are listed on the left
column. Ionic agents are listed on the top row, while the non-ionic agents are listed on the
bottom row. From Idee at al.84
Extracellular vs organ-specific
Finally, GBCAs can be classified according to their biodistribution as either
extracellular or mixed extracellular/organ-specific (hepatocyte). Extracellular agents
generally do not show appreciable binding to proteins within the body, and are solely
excreted by the kidneys (see Table 3.2).112 Organ-specific agents, which do bind to
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proteins within the body, are excreted in part by the biliary system, as well as the kidneys
(see Table 3.2).112 Although their immediate biodistribution following intravenous
injection are similar to extracellular agents, organ-specific agents allow for a longer
intravascular interval due to this protein binding and uptake by hepatocytes.112
Additionally, organ-specific agents often have higher relaxivity and demonstrate greater
(though clinically negligible) tissue brightening.112 Gadoxetic acid disodium (Eovist),
gadofosveset trisodium (Vasovist), and gadobenate dimeglumine (Multihance) are organspecific agents; the remainder are extracellular.112,113
Stability of GBCAs
The stability of the gadolinium chelated compounds is generally discussed via
two different, albeit similar concepts: thermodynamic stability and kinetic stability. All
chelates are nine-coordinate complexes, which have 8 binding sites for the metal center
(gadolinium ion) and a ninth site which is occupied by a water molecule.88 The stability
of the chelate is described by the equilibrium between the metal center (M), the ligand
(L), and the chelate (ML) as follows:88
[𝑴] + [𝑳] ⇋ [𝑴𝑳]

(3.2)

The thermodynamic stability is defined by the energy required for the release of
the gadolinium ion from the metalloligand.109 If the thermodynamic stability is high, then
less gadolinium ion is released from the chelate. If the thermodynamic stability is low,
then more Gd3+ ion is released from the metalloligand.109 It is generally described as the
final equilibrium state of the gadolinium-ligand complex, or how much gadolinium will
dissociate over time at a pH of 1.109
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Conditional stability, a constant, is described as the thermodynamic stability at a
physiologic pH of 7.4, and it is a more representative descriptor than thermodynamic
stability of the in vivo stability of these chelates in normal physiologic conditions within
patients.84
The kinetic stability of the chelate is characterized by its dissociation rate. It
describes how fast a steady-state equilibrium is achieved, and thus how fast the Gd3+ ion
is released from the chelated complex.109 If the kinetic stability is low, the dissociation
rate is high, and the gadolinium ion is released from the ligand quickly.84 If the kinetic
stability constant is low, then the dissociation rate is also low and the release of
gadolinium is too slow to be physiologically important.109 Kinetic stability is described as
the speed at which the ligand and gadolinium dissociate. It is generally reported at a pH
of 1, because if performed at physiologic pH of 7.4, some ligands would take months to
years to reach equilibrium.
Kinetic and conditional stability constants are given in Table 3.2, with other
safety and excretion considerations.
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Thermodynamic
stability
16.8
16.6
22.1
22.6
23.5
22
22.8
21.8

Omniscan

OptiMARK

Magnevist

MultiHance

Primovist/
Eovist

Vasovist/
Ablavar

ProHance

Gadavist/
Gadovist

15.5

17.2

18.9

18.7

18.4

18.4

15.0

14.9

Conditional
stability

7.9–24 hr

2–3 hr

N/A

N/A

N/A

10 min

N/A

<5 s

Kinetic
stability
(pH 1)

Renal

Renal

>1000 years
>1000 years

95% renal
4–5% hepatobiliary

50% renal
50% hepatobiliary

95% renal
4–5% hepatobiliary

Renal

Renal

Renal

Excretion

N/A

N/A

N/A

5–7 days

N/A

5–7 days

Kinetic
stability
(pH 7.4)

Chemical stability and excretion of the nine FDA approved gadolinium based contrast agents

Trade Name

Table 3.3
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High

High

Medium

Medium

Medium

Low

Low

Low

Kinetic
stability

25.4

19.3

9–60 hr

>1000 years
Renal

High

a: Low: long-time index < 0.3; Medium: long-time index 0.3 to 0.95; High: long-time index > 0.95. Long-time index is equal to the
ratio of the paramagnetic relaxation rates after 50 hours. N/A=not available. Adapted from Idee et al, Lohrke et al, and Ramalho et
al.84,103,109

Dotarem

Table 3.3 (Continued)
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Dosing
In people, enhancement of the MR signal occurs at a typically administered dose
of 0.1–0.2 mmol/kg, for magnet strengths over 0.5 Tesla, with a median lethal dose
(LD50) of approximately 10 mmol/kg, resulting in a safety factor of 50–100, superior to
that of iodinated compounds. Animal experiments have demonstrated excellent
cardiovascular tolerance, with toxic effects at high doses with the aforementioned LD50
in rats, mice, rabbits and dogs. Additionally, in rats and dogs administered doses up to 5
mmol/kg daily over a period of 4 weeks, subtoxic effects occurred resulting in
vacuolization of the proximal tubules (osmotic nephrosis).87 In veterinary patients, a
similar dose range is described, yet to date, dosages have been extrapolated from the
human literature or from clinical experience, and are largely unsubstantiated.114 An
optimal dose for veterinary patients has not been thoroughly investigated.114
Veterinary use of GBCAs
The use of gadolinium chelated contrast agents is also currently prevalent in
veterinary medicine. Early reports, beginning in the late 1980s, described the use of
gadolinium chelated contrast agents to better evaluate tissues such as the kidney and
brain, and also to better highlight such lesions as neoplasia (carcinoma) and hemorrhage
in research animals such as rabbits and rats.115-119 Veterinary institutions began installing
their own MR scanners in the 1990s, which were initially used to image the canine brain
and head.119-121 The applications of MRI were soon extended to include many spinal and
orthopedic conditions, and became available for the medical evaluation of many other
companion animal species, from cats to horses.120,122 MRI and GBCAs are now readily
clinically available for veterinary patients in both the academic and private sectors.120
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Adverse reactions to GBCAs
Although historically regarded as generally safe, with a low incidence of adverse
reactions and a high safety index, numerous reports of adverse reactions to intravenous
administration of GBCAs in both people and animals exist.86,123-130 In people, the
incidence of adverse events associated with GBCAs administration at clinical doses (0.1–
0.2 mmol/kg) is low and ranges from 0.07% to 2.4%.123,125,127,128,131-133 One institutional
study reports an adverse reaction in 5.9 per 10,000 injections, with a severe reaction
occurring every 1 in 40,000 injections.128 Although uncommon, reactions to intravenous
GBCA injection can be acute or delayed. Reactions occurring 30 minutes or more after
the administration of the chelated agent are considered delayed.134 Acute reactions are
seen more commonly, with 70% of these reactions occurring within the first 5 minutes
post-administration.134,135 Reactions can be further divided into mild, moderate, or
severe.132 Mild reactions generally do not require intervention, whereas moderate or
severe reactions require intervention in the form of antihistamines, bronchodilators,
emergency drugs including epinephrine and atropine, and hemodynamic support.129
Reported reactions include those that are mild and physiologic including injection
site coldness, warmth, pain, nausea with or without vomiting, headache, paresthesia, and
dizziness.133 In addition, allergic-like reactions similar to those seen with the intravenous
administration of iodinated contrast media, such as skin irritation, urticaria, facial edema,
nasal congestion, and throat symptoms (itching or tightening, 0.004%– 0.7%), as well as
transient dyspnea (4%–14%) are documented.133 Severe potentially fatal, life threatening
reactions including respiratory and cardiovascular arrest are exceedingly rare (0.001%–
0.01%), and there is an increased risk of adverse reaction in patients with underlying
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asthma or chronic respiratory disease.123-125,127,128,136-139 In addition, some
cardiodepressive and hypotensive effects are dose dependent in both people and rats.140142

The American College of Radiology (ACR) reports that additional risk factors for

adverse reactions include a previous reaction to a GBCA, history of allergic-like
reactions, and renal compromise.139 The incidence of mild adverse reactions (including
nausea and vomiting, cough, warmth, headache, dizziness, shaking, itching, and altered
taste sensation) for the various types of GBCAs is 0.11%, whereas the incidence of
severe reactions (including laryngeal edema, profound hypotension, and arrhythmias) is
0.02%.133
Nephrogenic systemic fibrosis (NSF)
In patients with acute renal injury or chronic renal disease, nephrogenic systemic
fibrosis (NSF), a systemic fibrotic disorder, has been strongly associated with the
intravenous administration of gadolinium chelated contrast agents.143-145 First described
in 2000, this rare disorder is characterized by scleroderma-like skin lesions and
widespread extracutaneous fibrosis, notably muscle, with more than 500 cases being
reported to the FDA since 2010.146 Although the disease occurs almost universally in
patients suffering from renal failure, there are reports of NSF-like lesions or gadolinium
toxicity in patients with normal renal function.147 The incidence of NSF has all but
disappeared with more judicious screening tests prior to GBCA administration and
careful selection of more stable agents in high-risk patients.139
GBCAs accumulate in the skin and internal organs of people with NSF.105,148,149
The use of extremely high (off-label) doses of GBCAs has largely been abandoned, and
off-label uses are uncommon within the latitude of reasonable, clinical, per case
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justification.139 Although not routinely performed in patients with hepatic or renal
insufficiency, the medical community is now beginning to entertain the clinical use of
fractional dosing (specifically 0.5 mmol/kg, with the most stable agents) in patients
undergoing serial examinations and patients under 18 years of age.150 Although rats given
high doses of GBCAs develop changes in their skin similar to affected NSF patients,
nephrogenic systemic fibrosis following intravenous gadolinium chelated contrast
administration is not reported in animals.104 Although the reason for this remains
unknown, it is possible that the shorter lifespan of our companion animals precludes
development of the disease. It is also possible that the disease does occur in companion
animals and has not yet been recognized.
Adverse reactions in veterinary medicine
The body of veterinary literature describing reactions to intravenously
administered GBCAs is limited, and thus the incidence of such reactions is currently
unknown. However, multiple reactions are described and include facial swelling,
hypotension, both bradycardia and tachycardia, and in one case cardiovascular collapse in
dogs and bradycardia, tachycardia, hypotension, and hypertension in both dogs and
cats.126,129,130,151,152
Survey of the American College of Veterinary Radiology
Due to the sporadic nature of reports of GBCA related adverse events and concern
amongst college members, the author designed a survey about the use of GBCAs in the
veterinary radiology community. This survey was distributed to the American College of
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Veterinary Radiology (ACVR) via an e-mail May 10, 2016. Results from this survey are
discussed in Chapter IV.
T1 hyperintensity following GBCA administration
The first report of unenhanced T1 hyperintensity in the brain was made in patients
with multiple sclerosis, with the report concluding that the hyperintensity was due to the
disease.153 In 2011, a report was made of regional T1 hyperintensity in unenhanced brain
images in patients with normal renal function.154 All of these patients had undergone
radiation therapy, and thus it was originally though that this hyperintensity was due to
radiation. However, more reports of unenhanced T1 hyperintensity emerged in patients
who had not undergone radiation therapy and did not suffer from multiple sclerosis.155-157
While this was first reported in adults with normal renal function, the hyperintensity has
also been shown in rats and in pediatric patients.155,157 All of the patients in those reports
had undergone multiple contrast-enhanced MRIs, and all had received linear agents.
The described hyperintensity is primarily seen in the dentate nucleus, pons,
globus pallidus, and basal ganglia.109,156,158-163 This hyperintensity is progressive with
increasing numbers (frequency) of dose administrations, and is independent of renal
function in these patients, however, this hyperintensity has not been shown in patients
administered macrocyclic GBCAs.153-157,160,162 In murine models, T1 signal
hyperintensity of the deep cerebellar nucleus occurs after multiple high intravenous
doses.109,155 This was not documented with similar doses of gadoterate meglumine, an
ionic macrocyclic agent.155
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Gadolinium tissue deposition
Gadolinium tissue deposition was first seen in the bones of patients who had
undergone femoral head and neck ostectomy following the intravenous injection of linear
GBCAs.164,165 Gadolinium deposition was next found in the skin of patients who were
suffering from NSF.148,149 Gadolinium deposition has more recently been discovered to
deposit within the human brain. Evaluation of post mortem brain samples of 13 people
with normal renal function undergoing multiple (at least 4) GBCA enhanced MRI studies
with IV gadodiamide, a linear agent, demonstrated dose dependent deposition of
gadolinium with transmission electron microscopy (TEM) and ICP-MS, independent of
renal function.109,166 Gadolinium brain deposits following multiple exposures to the linear
agents gadopentetate dimeglumine and gadoteridol in varying combinations have also
been shown.109,166 Globus pallidus, dentate nucleus and bone gadolinium deposition of
non-group 1 and macrocyclic agents is documented in 9 patients with systemic illness.113
Single or multiple administrations of both nonionic, macrocyclic agents (gadoteridol and
gadobutrol) and non-group 1, protein binding linear agents (gadobenate and gadoxetate),
result in brain deposition with an inability to pattern differentiate the levels of
deposition.113 Additionally, bone deposition levels of gadolinium were found in one study
to be a median 23 times greater than brain deposition.113 This finding raises a concern
that bone deposition may serve as a reservoir for continued deposition of the toxic
gadolinium into the blood or other organs. In people, a relationship between neural
gadolinium deposition and increased clinical disability, lesion load, brain atrophy or brain
irradiation may exist.109,153,154,166,167
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In murine models, cerebellar histologic gadolinium deposits are noted following
multiple doses of a linear agent, gadodiamide. Cerebellar, cerebral, and subcortical brain
gadolinium concentrations measured via inductively coupled plasma mass spectrometry
(ICP-MS) were significantly higher in rats given gadodiamide compared to gadoterate
meglumine.155 Both agents produce focal and generalized myoclonus over several hours
when injected into the lateral ventricle, with the cerebellar region having the greatest
sensitivity to gadodiamide.94 Significant increased seizure frequency is noted in 50% and
75% of dogs with osmotically induced disruption of the blood brain barrier (BBB) when
given gadopentetate dimeglumine at doses of 0.1 mmol/kg, and 0.2 mmol/kg,
respectively.168
Warnings and current recommendations for use and surveillance
The perception that chelation practically eliminates gadolinium ion disassociation
within the bloodstream and tissues is no longer a well-accepted theory and brain
deposition is now a dilemma facing physicians who rely on contrast enhanced MRI
(CEMRI) for increased specificity. In 2015, the FDA issued a GBCA safety
announcement.86,105,169 Investigation and research to understand the mechanisms of
gadolinium retention and risks posed with regard to neuronal brain deposition following
multiple IV administrations in people are ongoing.166,170 The FDA and National Institutes
of Health (NIH) advise limiting the use of GBCAs to necessary clinical circumstances,
reassessing the need for repetitive use in MRI studies of well-established protocols until
further evaluation of risks can be investigated and heeding NIH recommendations for
clinical use.169,170 Combined, mounting accumulative evidence resulted in a safety
warning announcement by the FDA, released on July 27, 2015.169 In summary, the
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statement announced safety concerns and a current ongoing FDA investigation through
the continued research through its National Center for Toxicological Research to
understand the mechanisms of gadolinium retention and to determine what risks, if any,
are posed by the deposition of gadolinium in the brains of human patients, following the
intravenous administration of multiple doses. The warning statement advises clinicians to
limit the use of GBCAs to necessary clinical circumstances and to reassess the clinical
necessity of repetitive use of GBCAs in MRI studies of established treatment protocols.
The statement further promises investigation into the safety of GBCAs and description of
the associated risks involved with their administration.169
Conclusion
The dog is a historically viable translational model for brain physiology and
disease states. Thus, improvements in our knowledge of advanced MRI techniques (or
ancillary techniques exclusive of conventional imaging) such as MRS; and evaluating
GBCA use, administration and tissue deposition in the brains of healthy dogs, not only
advances knowledge for the veterinary clinician, but provides a translational platform for
expanding knowledge for medical practitioners.69,70 Given the dose-dependent nature of
both adverse reactions to GBCA administration and gadolinium tissue deposition, finding
a lower clinical dose of GBCAs is an important problem to investigate. In addition,
research into gadolinium tissue deposition is non-existent in the dog; thus there is a need
to expand the literature on deposition in higher phylogenic species than mice.
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CHAPTER IV
CONSPICUITY OF VARIOUS LOW DOSES OF GADOLINIUM IN THE NORMAL
CANINE BRAIN AT 3 TESLA
Study purpose
The use and dosing of gadolinium-based chelated agents (GBCAs) in companion
animals has been anecdotal and extrapolated form murine dose research and dosing in
people. Several factors provided an impetus for investigating an ideal and minimum dose
needed to achieve adequate conspicuity of normal brain and other tissue lesions. First,
reports of reactions to contrast injection in companion animals are only sporadic in the
scientific literature. Second, a discussion at the Annual Scientific Meeting of the
American College of Veterinary Radiology in 2014 in St Louis, Missouri focused on
mounting concerns of unreported, but experienced adverse events ranging from urticaria
to death (Jennifer Gambino, personal communication, October 28, 2014). Finally, there
is recent concern in the medical field of gadolinium deposition in human tissues (skin,
bone and brain). The purpose of this portion of the study to was to determine if lowerthan accepted clinical doses of gadodiamide could be given in healthy dogs with adequate
conspicuity of normally enhancing structures
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Hypothesis
The author and cohorts hypothesized that normal patterns of enhancement would
be seen at fractional doses of gadolinium chelated contrast agents with adequate
conspicuity, in search for a viable lower dose for clinical use.
Methods and materials
Design and execution of in vivo portions of this study and subsequent surgical
laboratories were subject to institutional review board oversight, (Institutional Animal
Care Use Committee protocol numbers 15012, 12065, and 15075). Financial support was
provided by Dr. Gambino through the Department of Clinical Sciences, and the American
College of Veterinary Radiology. In addition, Dr. Gambino provided direction and had
oversight of all aspects of the current study concept, design, drafting, revision, and final
approval and had full control of the acquisition, analysis, and interpretation of all data.
Study population
This prospective, pilot study population consisted of 8 healthy juvenile purposebred hound dogs. Ages ranged from 5 to 13 months (mean=8.6 months, IQR=5 months).
Two dogs were intact males, five were intact females, and one was a spayed female.
Weights ranged from 17.3–24.8 kg (mean=23.76 kg, IQR=8.65). Dogs were deemed
normal based on physical and neurophysical examination performed by a first-year
radiology resident, laboratory animal veterinarian, and a board-certified neurologist.
Complete blood count, serum biochemistry, serum occult heartworm, and serum titers for
Ehrlichia canis, Rickettsia rickettsii, Borellia burgdorferi, and Babesia canis (ProtaTek
Reference Laboratory, Mesa AZ) were performed. All study subjects underwent CT scout
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scanning with a 64 detector helical CT (Lightspeed VCT 64–slice, GE Healthcare,
Milwaukee, WI) scanner for pre-MRI whole body metal (implanted or ingested)
screening prior to MRI of the brain. Following MRI examination all subjects underwent
cerebrospinal fluid centesis and analysis for cytology and West Nile virus titer testing
(Diagnostic Center for Population and Animal Health, Lansing MI). Further exclusion
criteria for subject selection was not applied.
MRI imaging
Technical information: conventional magnetic resonance imaging
A daily quality assurance for functional magnetic resonance imaging (fMRI) was
performed the morning prior to all MRI scanning, consisting of a base EPI sequence on a
phantom. In addition, a week or less prior to all scans, an American College of Radiology
(ACR) phantom scan was performed, the results of which are evaluated yearly by a
licensed medical physicist.
All dogs were sedated with acepromazine (0.01 mg/kg, PromAce, Fort Dodge
Animal Health, Overland Park, KS) and hydromorphone (0.1 mg/kg, Dilaudid, WestWard, Eatontown, NJ) intramuscularly. Animals were induced with propofol (2.3 mg/kg,
PropoFlo, Abbot Animal Health, Abbott Park, IL) and were maintained on an admixture
of isoflurane (Attane, Piramal Healthcare, Bethlehem, PA) inhalant anesthesia and
oxygen according to a standard clinical protocol and under supervision of our
institutional anesthesia service. Conventional morphologic MR was performed with a 3T
magnet (Signa 3T Excite, General Electric Healthcare, Milwaukee, WI). All animals
were scanned in sternal recumbency with a quadrature knee coil (M1385AM, IGC
[Intermagnetics General Corporation], Latham, NY). A typical clinical conventional MR
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imaging protocol was performed in multiple image planes to include the following:
sagittal T1-weighted (T1-W) Fluid Inversion Recovery (FLAIR); dorsal T2-weighted
(T2-W); sagittal and transverse T1-W fast spoiled gradient echo (FSPGR); transverse T2W FLAIR, T2* fast gradient echo (FGRE), transverse diffusion tensor (DTI); transverse
diffusion weighted imaging with apparent diffusion coefficient mapping (DWI, ADC);
and transverse time-of-flight (TOF) imaging; and a 3-D reconstructable, transverse T1-W
FSPGR series following the intravenous administration of a gadolinium chelated contrast
agent, gadodiamide (Omiscan, 0.5 mmol/mL, General Electric Healthcare, Milwaukee,
WI). Dogs were administered variable, fractional doses of the contrast agent as follows:
0.1 mmol/kg (n=2), 0.05 mmol/kg (n=2), 0.025 mmol/kg (n=1), 0.0125 mmol/kg (n=1),
and 0.006 mmol/kg (n=1) via the right cephalic vein. Following intravenous contrast
administration, intravenous fluids (0.9% sodium chloride, Baxter Healthcare, Deerfield
IL), at a standard anesthetic flow rate dose of 5 mL/kg, were administered. Morphologic
images were reviewed by a board-certified radiologist and a second-year imaging
resident. Animals were included only if morphologic MR brain images were normal.
Contrast administration
A single, dose of gadodiamide was administered intravenously via a cephalic vein
at various doses given below.
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Table 4.1

Intravenous dosing scheme of gadodiamide (Omniscan) administered to the
study population consisting of eight purpose-bred hound dogs

Number of dogs

Administered dose
(mmol/kg)

Fraction of 0.1 mmol/kg
dose

1

0.006

1
16

1

0.0125

1
8

2

0.025

1
4

2

0.05

1
2

2

0.1

1

The administered intravenous gadodiamide was followed by intravenous fluids
(0.9% sodium chloride, Baxter Healthcare, Deerfield IL). A 3-D reconstructable,
transverse T1-W FSPGR series was acquired following the administration of the contrast
agent.
Following imaging, all dogs underwent cisternal cerebrospinal fluid centesis by a
board-certified veterinary neurologist immediately following imaging and prior to
anesthesia recovery. All dogs then received carprofen (4 mg/kg, Rimadyl, Zoetis,
Florham Park, NJ) subcutaneously and recovered from anesthesia uneventfully.
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Histopathology
Following imaging and recovery, all dogs were surrendered to an unrelated nonimaging terminal surgical laboratory under a separate institutional protocol. Animals
were humanely euthanized following a second anesthetic event and terminal surgical
laboratory, 3–7 days after administration of the contrast agent. Procedures performed
during this surgical laboratory included enterotomies, small intestinal resection and
anastomoses, and renal biopsies, but did not involve the central nervous system or brain
in any way. The brains of each of the subjects were harvested no more than four hours
following euthanasia, and in the interim, were kept on ice. Formalin-fixed neurologic
tissue from the frontal, parietal, and piriform lobes, thalamus, cerebellum, brainstem,
motor cortex, and hippocampus, were submitted for histopathologic evaluation to confirm
the normal status of the tissue.
Data analysis
T1-W FSPGR transverse and sagittal images pre- and post-contrast administration
were evaluated.
Lossless tagged image file format (TIFF) images of the transverse T1-W pre- and
post-contrast images, all obtained at the same window level and width (window
level=2501, window width=498), were anonymized and randomized using an available
web-based random-number generator (www.random.org, accessed November 10, 2015).
Images were then reviewed by two board-certified radiologists and a second-year
imaging resident blinded as to the doses of contrast given and whether or not images
were acquired in the pre- or post-contrast stage of imaging. Each participant evaluated the
regions of interest that included regions of brain considered to enhance mildly to
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moderately in normal people and dogs administered a GBCA. Images were then assigned
a subjective and arbitrary score for the degree of enhancement perceived, at the following
regions: olfactory bulb, dorsal sagittal sinus, cerebral cortex, third ventricle, lateral
ventricle, thalamus, interthalamic adhesion, piriform lobe, pituitary, trigeminal nerve,
mesencephalic aqueduct, cerebellum, fourth ventricle, and meninges. Images were
subjectively scored as follows: 0=no contrast seen; 1=poor enhancement of normally
enhancing structures (minimal contrast seen), 2=good enhancement of normally
enhancing structures, and 3=excellent enhancement of normally enhancing structures
(high contrast conspicuity).
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Tagged image file format (TIFF) images of T1-weighted transverse images
following various doses of gadodiamide in four normal dogs
Dogs were given one of the following doses of contrast: A– 0 mmol/kg, B– 0.0125
mmol/kg, C– 0.025 mmol/kg and D– 0.1 mmol/kg (D). Images were scored by all three
observes as a 0 (A), 1 (B), 2 (C), and 3 (D).
A novel computer program was created to analyze the images for the presence of
contrast. Pixel intensity probability mass function (PMF) of graylevel* values were used
as features. Features were optimized with Fisher’s Linear Discriminant Analysis. Linear
classifier decided for each image either no-enhancement or enhancement using Leave-
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one-out analysis. Images were converted to grayscale (pixel values 0 to 255) for the
analysis.
Statistical analysis
Kappa statistics were used to evaluate the performance of the two board-certified
radiologists and imaging resident compared to each other as well as compared to the
known pixel intensity for those regions, which was used as the gold standard. In addition,
an interclass correlation coefficient (ICC) was performed to evaluate agreement between
the three observers. All statistics were performed by a board-certified veterinary
epidemiologist, using SAS for Window 9.4 (SAS Institute, Inc., Cary, NC, USA).
Gadolinium based contrast use by the American College of Veterinary Radiology: a
survey
In order to more accurately determine the use of GBCAs in the veterinary
radiology community, the author designed a survey regarding the use of GBCAs in the
veterinary radiology community. This survey was distributed to Diplomates of the
American College of Veterinary Radiology (ACVR) via an e-mail May 10, 2016 and
results were accepted until October 10, 2016.
The questions were as follows:
1. Do you routinely use gadolinium chelated contrast agents as part of your
MRI studies?
2. What contrast agent do you use?
3. What dose of contrast do you typically give?
4. Have you noticed any adverse reactions to gadolinium chelated contrast
agents in your patients?
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5. If yes, can you please describe these reactions?
All participant respondents remained anonymous.
Results
Conventional and advanced MRI examinations were successfully performed in all
dogs and deemed normal by a board-certified veterinary radiologist and board-certified
veterinary neurologist. Advanced protocols demonstrated normal brain diffusion and
perfusion. All images were of excellent diagnostic quality and none were excluded from
the image scoring. No complications were observed in any dog secondary to the
phlebotomy, gadolinium contrast administration, MRI examinations or cerebrospinal
fluid centesis. All hepatic and renal serum biochemistry values were normal in all dogs.
Infectious disease titers for Ehrlichia canis, Rickettsia rickettsii, Borellia burgdorferi,
and Babesia canis were negative, all dogs tested heartworm negative, and CSF cytology
results were unremarkable in all animals. All dogs exhibited normal MR brain
morphology with normal patterns of contrast enhancement and all animals recovered
uneventfully from anesthesia.
Agreement
Initially, 5 reviewers were included in the study, including two board-certified
radiologists, a second-year imaging resident, first-year imaging resident, and imaging
intern. The results from the first-year imaging resident and imaging intern were excluded
from analysis due to these two reviewers inadvertently revealing results to each other.
When the remaining three results were analyzed, agreement between the board-certified
radiologists (reviewers 1 and 2) was good (Kappa=0.64). Agreement was also good
92

between both board-certified radiologists and the imaging resident (reviewers 1 and 3,
and 2 and 3; Kappa score=0.57 and 0.66, respectively). The interclass correlation
between the 3 reviewers was excellent (ICC=0.79). When images were considered by
score and reviewer, the two radiologists were very similar, while the less experienced
imaging resident tended to score the images higher (or over interpret the degree of
contrast dose present).
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Image Score by Reviewer and Dose
3.5

Image Score

3
2.5
2
1.5
1
0.5
0

0

0.006

0.0125

0.025

0.05

0.1

GBCA Dose (mmol/kg)
Radiologist 1

Radiologist 2

Resident

Image score by dose (in mmol/kg) and by reviewer.
Images scores were assigned to randomized, lossless, TIFF images by 3 reviewers (of
varying levels of experience). A subjective assignment of scoring was performed by each
of the participating individuals. Subjective scoring by reviewer, dose and correlation to
actual intravenous dose administered (mmol/kg), is shown in graphical representation.
Arbitrarily assigned, subjective image scoring was based on a scale of 0–3, with 0=no
contrast seen; 1=poor enhancement of normally enhancing structures (minimal contrast
seen], 2=good enhancement of normally enhancing structures, and 3=excellent
enhancement of normally enhancing structures [high contrast conspicuity]. Notice the
radiologists’ scores are very similar, while the resident tended to score images higher
than that of the radiologists. Notice also, fair to good agreement at the 0.125 mmol/kg
dose, and excellent agreement at 0.05 and 0.1 mmol/kg, respectively.
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Conspicuity Results

Number of images

25
20
15
10
5
0

0

1

2

3

Score
Radiologist 1

Radiologst 2

Resident

Number of images given each score by reviewer
Number of images scored 0, 1, 2, or 3 as scored by each reviewer (Radiologist 1,
Radiologist 2, and radiology resident). Again notice the resident tended to score images
higher than the radiologists. Notice the relatively good agreement for the number of doses
that scored a 3 or excellent conspicuity. All reviewers over-interpreted the 0.5 mmol/kg
dose as a 0.1 mmol/kg.
A total of 24 images were scored as 0, 46 were scored as 1, 30 were scored as 2,
and a total of 62 images were scored as 3 (excellent conspicuity). Twenty-six of the
images scored as a 3 from dogs administered the 0.05 mmol/kg dose, which corresponds
to 42% of the images scored as 3 and 72% of the 0.05 mmol/kg images. Thirty-four of
the images scored as a 3 were from dogs administered the 0.1 mmol/kg dose, which
corresponds to 55% of the images scored as 3 and 94% of the 0.05 mmol/kg images. All
images were reviewed in the same ambient conditions, on the same computer set to the
same brightness level. Window and leveling capabilities were absent for all images.
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Image Scoring by Dose
Number of Images

70
60
50
40
30
20
10
0

0

1

2

3

Image Score
0

0.006

0.0125

0.025

0.05

0.1

Images scored by dose by three reviewers
Image scoring presented by dose. Note that the majority of images scored a 3 (excellent
conspicuity) were from dogs administered either a 0.05 mmol/kg dose (blue) or a 0.1
mmol/kg dose (green), comprising 72% of dogs receiving the 0.05 mmol/kg dose and
94% of the dogs receiving the 0.1 mmol/kg dose.
The novel custom automated detection software scored 48/48 (100%) images with
contrast as contrast enhanced, and scored 2/6 (33.3%) of the images without contrast as
non-enhanced. Thus the program had a false positive rate of 66.6% and a false negative
rate of 0%. Upon review, it was determined that the computer was erroneously reading
phase-encoding artifact (and subsequent arterial flow hyperintensity) as contrast
enhancement. When phase-encoding artifacts were removed from the image, the
computer classified 6/6 (100%) of the images without contrast as non-enhanced,
decreasing the false positive rate to 0%.
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Survey results
There were a total of 26 responses to the survey. Given 605 active diplomates in
the ACVR, this is a response rate of 4.3%. Twenty-five of 26 respondents (96%) reported
using GBCAs in their practice. The most commonly used agents were gadopentetate
(Magnevist, 13/25, 52%), gadodiamide (Omniscan, 5/25, 20%), and gadobenate
(Multihance, 4/25, 16%). Gadoteridol (ProHance) was reported twice (8%) and
gadoversetamide (OptiMARK) was reported once (4%). The most commonly used dose
was 0.1 mmol/kg with a dose range of 0.1–0.15 mmol/kg documented.
Twenty-three of 25 respondents reported seeing no adverse events associated with
GBCA use (88.5%). The reported adverse events included bradycardia, tachycardia,
hypertension, and allergic-type reactions. One event of hypotension was severe and
resulted in euthanasia of the patient.
Discussion
Adverse effects
No adverse reactions to the gadodiamide injections were seen in the current study
population. This was expected, as there are only sporadic reports of reactions to GBCA
administration in veterinary medicine, and the incidence of reactions in people is very
low, ranging from 0.06% to 0.11%.123,126,128,133
Conspicuity
When each image was graphed by score and reviewer, both boarded radiologists
were very similar in their scoring. The less experienced radiology resident tended to score
images higher than the radiologists; this is likely due to the relative inexperience with
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MR images of the resident compared to the more experienced radiologists. However, the
overall trend of scoring was similar across all three reviewers, indicating that despite the
resident generally scoring images higher than the radiologists, the scoring between the
images was consistent amongst all reviewers. The interclass correlation coefficient of
0.79 indicated excellent agreement amongst the three reviewers.
When broken down into the described 0–3 categories, the majority of both the 0.1
mmol/kg (94%) and the 0.05 mmol/kg (72%) doses were scored as a 3, or “excellent
conspicuity.” Results from this pilot study indicate that 0.05 mmol/kg gadodiamide was
subjectively assessed as excellent and thus, should be considered as a viable, fractional
clinical dose for brain imaging since it provides adequate conspicuity of normally
enhancing brain structures in a healthy sub-population of young, purpose-bred dogs.
Importantly, this study included the subjective assessment of normally enhancing
structures in healthy dogs. Enhancement in the brain is the result of one of two separate
primary processes: intravascular or vascular, and interstitial or extravascular
enhancement.171 Following intravenous administration, the blood concentration of
GBCAs rises rapidly. The concentration creates a gradient across the capillary endothelial
membrane, and in regions with relatively free capillary permeability, contrast
accumulates in the perivascular interstitial fluid. In the brain, the blood brain barrier
(BBB) prevents this leakage normally. Thus, the structures which normally enhance are
those outside of the BBB, including the meninges and choroid plexus of the ventricles.
When the BBB is disrupted, however, as with a neoplastic or inflammatory condition,
contrast is able to accumulate at the sites of disruption.171 Normal interstitial
enhancement is directly related to alterations in the permeability of the BBB, while
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intravascular enhancement is proportional to increases in blood flow or blood volume.171
Additionally, interstitial enhancement in MR requires both free water and gadolinium to
be present; therefore, if a tissue does not contain free water, no contrast enhancement will
be seen.171 Dura mater, for instance, is extra-axial and does not have a BBB, but it lacks
sufficient water content for the required T1 shortening to show contrast enhancement.171
Study limitations
There were several limitations to this study. In this study, the author strove only to
evaluate normally enhancing structures in healthy dogs, which is not duplicative of the
typical clinical setting. Abnormal enhancement patterns of pathologic disease states were
not evaluated or quantified. Thus, work beyond the limitations of a descriptive pilot study
are required to verify the validity of this dose in clinical patients having a variety of
central nervous system diseases. The study herein provides a basis for future
investigation and comparison of the clinical efficacy of fractional dosing. Further, study
population numbers were limited to only eight dogs, which limited the study power. The
limited population size was partially due to the fact that this study was intended as a pilot
study. This limitation was also due to the ethical and financial considerations inherent to
veterinary MR research in dogs. Attempts to offset this limitation and increase power
were made by including multiple images from each dog for the evaluation of normally
enhancing structures and the multiple fractional doses. A larger number of dogs,
investigating a larger but more targeted range of doses around the clinically accepted 0.1
mmol/kg dose, may have produced stronger results. However, dog numbers were limited
by financial, ethical, and timing constraints. Further, a scale of computer assigned pixel
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values can be assigned to a dose correlated reviewer viewing scheme where 0, 1, 2, 3, 4,
etc. can be correlated to an assigned dose
The authors did not investigate the typically reported higher end of the dose range
administered to people and companion animals (0.2–0.3 mmol/kg). The clinical protocols
employed at the author’s institution do not include doses greater than 0.1 mmol/kg, and
as excellent conspicuity of contrast is achieved at this dose, this study evaluated the
conspicuity of equal and lower doses than those given to veterinary patients at the
author’s institution. Similarly, the author chose to only investigate one GBCA, the linear
agent gadodiamide. This agent was chosen because it is the agent used in clinical patients
at the author’s institution in both veterinary patients and in people seen at the adjacent
clinical practice that shares the 3T magnet. Although there are mild differences between
T1 shortening times of different GBCAs (as shown in Figure 4.5), there is no literature
that exits regarding the clinical performance of GBCAs which indicates that any one
compound is superior to other GBCAs. Thus, it is unlikely that the choice to use only one
GBCA negatively affected the results of this study. Reviews did not have the ability to
manipulate the window or level of the images presented. Results may have been different
had reviewers had the ability to alter the window and level, in that lower doses may have
been deemed more adequate.
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T1 shortening times of various GBCAs, as a function of their gadolinium
concentration.
These times were calculated from relaxivities in blood, which was first reported by Roher
et al in 2005.172 Image from Kanal et al 2014.173
Finally, there is no current “gold standard” against which to judge the
performance of the reviewers to validate the findings described. The described computer
program is currently able to determine if contrast was administered at a high rate of
success, however these results say nothing about levels of conspicuity. Proprietary
software is currently being devised with novel computer algorithms for the evaluation of
contrast enhanced images using pixel intensity for which to compare results of the current
study, as well as future results from clinically diseased patients. The eventual goal is to
evaluate images for the degree and presence of contrast enhancement following fractional
dose administration that may be below human levels of detectability. The human eye is
only able to detect 30 shades of grey, and humans are thus unable to see many of the
available shades present on a computer screen.174 Such work may mitigate the need for
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normal, current dose protocols and will aid in the evaluation of computer, radiologist and
resident performance.
Conclusions
In conclusion, the results show that the 0.05 mmol/kg and 0.1 mmol/kg doses of
gadodiamide provide excellent conspicuity of normally enhancing structures in healthy
dogs. There was an excellent interclass correlation coefficient for the three reviewers, and
thus, excellent agreement. Based on these results, the author proposes fractional dosing
for veterinary, clinical, contrast-enhanced MR examinations in general, inclusive of
patients who may be at an increased risk for adverse events. No risk factors have been
definitely discovered in companion animals, likely due to the sporadic nature of the case
reports describing these events. Although conjectural, as limited literature exists, a
potential at risk population might include individual animals having a previous history of
an adverse event, asthma or other chronic respiratory diseases, or renal compromise as is
true in people. Future work with the 0.05 mmol/kg dose is needed to evaluate the clinical
viability of this dose for the evaluation of various intracranial and extracranial disease
states, including those that arise from neoplasia, inflammation, infection and injury.
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CHAPTER V
INVESTIGATION OF NEURONAL DEPOSITION OF GADOLINIUM IN NORMAL
DOGS FOLLOWING A SINGLE INTRAVENOUS EXPOSURE TO VARIOUS
DOSES OF GADODIAMIDE
Study purpose
Gadolinium tissue deposition has been demonstrated in both people and murine
models. Tissue deposition has been demonstrated in cadaveric samples of brain, bone and
skin in clinical human patients with numerous disease states, including neoplasia, hepatic
cirrhosis, and systemic lupus erythematosus; and in mice receiving large, non-clinical
doses of gadolinium.113,155 No studies exist determining if this deposition is seen in
healthy non-murine, animals receiving a single, clinical (or subclinical) dose. The
purpose of this portion of the study was to evaluate the neuronal deposition of varying
(subclinical) fractional doses of a single, in vivo administration of intravenous
gadodiamide, in 13 healthy canine subjects (having normal hepatic and renal function),
with a 14th dog serving as a control following the administration of an intravenous
placebo.
Hypothesis
The author and cohorts hypothesized that neural deposition would be seen in the
brains of all dogs receiving intravenous gadodiamide, regardless of the dose
administered, that no deposition would be seen in a control dog given an equal volume
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saline bolus and that the gadolinium deposition would demonstrate both dose dependency
and regional affinity.
Methods and materials
Design and execution of in vivo portions of this study and subsequent surgical
laboratories, were subject to institutional review board oversight, (Institutional Animal
Care Use Committee protocol numbers 15012, 12065, and 15075 and 16010). Financial
support was provided by Dr. Gambino through the Department of Clinical Sciences; and
by grants from Mississippi State University and the American College of Veterinary
Radiology CT and MR society. In addition, Dr. Gambino provided direction and
oversight of all aspects of the current study concept, design, drafting, revision, final
approval and the acquisition, analysis, interpretation and full control of all data.
Study design and animal subject population
Fourteen, healthy, live purpose-bred hound dogs were evaluated following a
single, IV exposure to gadodiamide (range 0.006 mmol/kg–0.1 mmol/kg) or saline. Eight
of these dogs were the dogs described in Chapters II and IV above. All dogs had a
physical and neurophysical examination performed by the institutional laboratory animal
veterinarian, diagnostic imaging resident, and board-certified neurologist, complete blood
count (CellDyn 3700, Abott Diagnostics, Santa Clara, CA), serum biochemistry (Vet
Axcell, Alfa Wasserman Inc, West Caldwell, NJ), and negative serum occult heartworm
antigen testing. Dogs were divided into 3 groups. As part of another study, dogs of group
1 underwent testing for infectious disease serum titers for Ehrlichia canis, Rickettsia
rickettsii, Borellia burgdorferi, and Babesia canis (ProtaTek Reference Laboratory, Mesa
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AZ), MRI examination, cerebrospinal fluid centesis (CSF), analysis and cytology and
West Nile virus titers from CSF (Diagnostic Center for Population and Animal Health,
Lansing MI). Blood sample collection for all testing was performed 1 day (group 1) or 8
weeks (groups 2 and 3), (median=1, mean=24.6, IQR=55), prior to GBCA exposure.
Eight dogs in group 1 underwent brain MRI with a single, IV gadodiamide injection as
follows: 0.006 mmol/kg (1 dog), 0.0125 mmol/kg (1 dog), 0.025 mmol/kg (2 dogs), 0.05
mmol/kg (2 dogs) or 0.1 mmol/kg (2 dogs). Dogs of group 1 underwent cisternal
cerebrospinal fluid (CSF) centesis following contrast enhanced MRI (CEMRI). Five dogs
in group 2 received IV gadodiamide as follows: 0.0125 mmol/kg (1 dog), 0.025 mmol/kg
(1 dogs), 0.05 mmol/kg (2 dogs), and 0.1 mmol/kg (2 dogs). Dogs in group 2 did not have
testing for infectious disease titers and did not undergo preemptive MRI or subsequent
cisternal CSF centesis. Group 3 was comprised of a single control dog that received a
single, placebo volume of 3 mL saline (0.9% sodium chloride, Baxter Healthcare,
Deerfield IL), and did not receive a GBCA.
Group 1 dogs were humanely euthanized within 3–7 days following the single
exposure, whereas dogs of group 2 and 3 were humanely euthanized within 8.3–8.9 hours
of the single exposure to gadodiamide or saline injection. Euthanasia was accomplished
via intravenous barbiturate overdose in all animals. Neuronal tissues from the frontal,
parietal, and piriform lobes, thalamus, cerebellum, brainstem, motor cortex, and
hippocampus were evaluated histopathologically to confirm normal brain status in all
groups, as described in Chapter II. Additionally, 1 cubic cm brain samples from the
parietal and piriform lobes, thalamus, cerebellum, frontal lobe white matter and brainstem
were harvested from all dogs and was analyzed post mortem with inductively-coupled
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plasma mass spectrometry ICP-MS, scanning electron microscopy (SEM) and
transmission electron microscopy (TEM) to evaluate for neuronal gadolinium deposition.
All evaluators were blinded as to the doses administered to each of the dogs.
Exclusion criteria included abnormal neurophysical examination, CBC, blood
chemistry, urinalysis, positive infectious disease titers, positive HTW-Ag test, abnormal
brain MRI findings, pre-existing history of IV GBCA administration or an adverse event
following the IV GBCA administration. Additionally, any subjects having complications
related to anesthetic and imaging events, CSF centesis, surgical interventions (group 2),
or a mean arterial blood pressure below 60 mmHg during the anesthetic event following
the gadodiamide administration (group 2), were excluded.
MRI imaging and GBCA administration
All dogs had similar premedication, anesthetic induction protocols for two
antemortem anesthetic events prior to euthanasia. Dogs were premedicated with
acepromazine (0.01 mg/kg, PromAce, Fort Dodge Animal Health, Overland Park, KS)
and hydromorphone (0.1 mg/kg, Dilaudid, West-Ward, Eatontown, NJ) intramuscularly
(IM). For MR imaging (group 1) and/or surgical procedures (groups 1–3), general
anesthesia was induced with IV propofol (2.3 mg/kg, PropoFlo, Abbot Animal Health,
Abbott Park, IL) and were maintained on an admixture of isoflurane (Attane, Piramal
Healthcare, Bethlehem, PA) inhalant anesthesia and oxygen according to standard
clinical institutional protocols under supervision of the anesthesia service. Dogs
recovered uneventfully from the first anesthetic events.
All study subjects underwent CT scout scanning with a 64 detector helical CT
(Lightspeed VCT 64-slice, GE Healthcare, Milwaukee, WI) scanner as a whole body
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metal (implanted or ingested) screening prior to MRI of the brain. MRI was acquired
using a 3T magnet (Signa 3T Excite, General Electric Healthcare, Milwaukee, WI). All
animals were scanned in sternal recumbency with a quadrature knee coil (M1385AM,
IGC [Intermagnetics General Corporation], Latham, NY). A typical clinical conventional
MR imaging protocol was performed in multiple image planes to include the following:
sagittal T1-weighted (T1-W) Fluid Inversion Recovery (FLAIR); dorsal T2-weighted
(T2-W); sagittal and transverse T1-W fast spoiled gradient echo (FSPGR); transverse T2W FLAIR, T2* fast gradient echo (FGRE), transverse diffusion tensor (DTI); transverse
diffusion weighted imaging with apparent diffusion coefficient mapping (DWI, ADC);
and transverse time-of-flight (TOF) imaging; and a 3-D reconstructable, transverse T1-W
FSPGR series following the intravenous administration of a gadolinium chelated contrast
agent, gadodiamide (Omiscan, 0.5 mmol/mL, General Electric Healthcare, Milwaukee,
WI). Typical conventional MRI acquisition protocol was as follows: 512x512 matrix, 2
number of signal averages, 140 mm reconstruction diameter, and 2.4 mm slice thickness
and interval, respectively. Please refer to Appendix C for more information regarding MR
sequence parameters.
As part of the MRI examination, eight dogs (group 1) received a single IV dose of
gadodiamide at one of the following doses: 0.006 mmol/kg (1 dog), 0.0125 mmol/kg (1
dog), 0.025 mmol/kg (2 dogs), 0.05 mmol/kg (2 dogs) or 0.1 mmol/kg (2 dogs), via the
right cephalic vein, for contrast enhanced MRI. Intravenous fluids (5 mL/kg/hr, 0.9%
sodium chloride, Baxter Healthcare, Deerfield IL) were administered following the
injection. In the immediate post-imaging interim, dogs were transferred to an animal
recovery bay for cisternal cerebrospinal fluid centesis, which was performed by a board107

certified veterinary neurologist prior to recovery. A single subcutaneous injection of
carprofen (4 mg/kg, Rimadyl, Zoetis, Florham Park, NJ) was administered and dogs
recovered uneventfully.
Six additional dogs (groups 2 and 3) had tibial osteotomy procedures for an
unrelated non-steroidal anti-inflammatory drug medication trial during the first anesthetic
event and did not undergo preemptive CT or MRI. Sixty-two days following the initial
anesthetic and surgical event, dogs of group 2 were anesthetized for the second event, a
terminal surgical laboratory, in similar fashion, upon which IV gadodiamide was
administered as follows: 0.025 mmol/kg (1 dog), 0.05 mmol/kg (2 dogs), 0.1 mmol/kg (2
dogs) and a placebo dose of IV saline (2.5 mL, 0.9% sodium chloride, Baxter Healthcare,
Deerfield IL), via the right cephalic vein, followed by IV fluids (5 mL/kg/hr, 0.9%
sodium chloride, Baxter Healthcare, Deerfield IL). The single dog in Group 3 underwent
similar anesthetic protocols as dogs of group 3, however saline (3mL, 0.9% sodium
chloride, Baxter Healthcare, Deerfield IL), was administered IV, as a placebo, rather than
gadodiamide. CSF centesis and the administration of periprocedural carprofen, were not
performed in dogs of group 2 and 3.
All dogs were subsequently surrendered to the unrelated, ethically preapproved,
terminal surgical laboratories. Surgical interventions performed in all dogs at the time of
the second anesthetic events for a terminal teaching laboratory were primarily
gastrointestinal in nature, with no surgeries involving disruption of the blood brain barrier
(BBB). Following the laboratory, dogs were humanely euthanized via intravenous
injection under general anesthesia (4.5 mL/kg, Beuthanasia-D Special, Schering-Plough
Animal Health Corp., Kenilworth, NJ).
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Tissue processing and histopathology
Fourteen dogs underwent necropsy immediately following euthanasia with brain
harvesting and sectioning performed by a single board-certified veterinary pathologist.
Transverse samples were collected for histopathology from each of following regions in
all dogs: the frontal, parietal, and piriform lobes, thalamus, cerebellum, brainstem, motor
cortex, and hippocampus. The tissues were processed routinely, embedded in paraffin
wax, sectioned at 4 microns and stained with hematoxylin and eosin for microscopic
examination. For dogs of group 1, whole-brain specimens were removed at necropsy and
immersion fixed in 10% neutral buffered formalin for 4-weeks. Bihemispheric, 1 cubic
centimeter brain tissue samples from the frontal lobe white matter, parietal lobe, piriform
lobe, thalamus, cerebellum, and brainstem were then submitted for ICP-MS. For dogs of
groups 2 and 3, 1 cubic centimeter brain samples were collected from frontal lobe white
matter, parietal lobe, piriform lobe, thalamus, cerebellum, and brainstem, immersion
fixed in 10% neutral buffered formalin. Additional samples from the frontal lobe white
matter, parietal lobe, piriform lobe, thalamus, cerebellum, and brainstem, were placed in
Karnovsky’s fixative (2% paraformaldehyde + 2.5% gluteraldehyde in 0.1 M sodium
cacodylate buffer). Finally, thin slices of brain from the frontal lobe white matter, parietal
lobe, piriform lobe, thalamus, cerebellum, and brainstem of the contralateral hemisphere
were collected and frozen fresh at –80 degrees Celsius.
Fixed brain samples from dogs of group 1, and fresh frozen and fixed samples
from dogs of group 2 and 3, were submitted for ICP-MS evaluation. Combined, a total of
120 brain tissue samples were evaluated for gadolinium quantification from the
aforementioned lobes of interest.
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For dogs of group 1, mean formalin fixation time for samples prior to ICP-MS
was 200 days (range=150–278 days). For dogs of group 2 and 3, formalin sample time
for samples prior to ICP-MS was 22 days. Median fixation time in electron microscopy
fixative, prior to SEM and TEM, was 36 hours. Formalin-fixed brain samples from dogs
of group 1 and fresh and formalin-fixed brain samples from dogs of group 2 and 3,
respectively, were archived in the author’s institutional bio-specimen repository.
Formalin-fixed brain tissue samples from dogs with the highest lobar gadolinium
depositions from both groups were submitted for SEM and TEM for gadolinium
identification.
Inductively-coupled plasma mass spectrometry gadolinium analysis
Ex vivo brain samples from all dogs were analyzed and quantified for gadolinium
deposition using ICP-MS at the Diagnostic Center for Population and Animal Health at
Michigan State University by a board-certified toxicologist. The selected regions were
trimmed from fixed tissue and briefly wicked with a Kimwipe (Kimberly Clark
Professional, Roswell, GA) before being placed in sterile transfer tubes. The
aforementioned lobar samples from all dogs were individually labeled, stored, and
refrigerated in individual tissue vials during shipment. One cubic centimeter, formalinfixed samples from the white matter of the frontal lobe, parietal lobe, piriform lobe,
thalamus, cerebellum, and brainstem of each of the dogs were submitted and were dried
for approximately 20 hours at 95o Celsius in a gravity convection oven (Lindberg/Blue M
model G01305A, VWR, Radnor, PA). The laboratory was blinded to the contrast doses
corresponding to each of the samples. Each standard solution (200 L), spiked control
and unknown sample was pipetted and diluted with 5mL of a solution containing 0.5%
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EDTA and Triton X-100, 1% ammonia hydroxide, 2% propanol and 20 ppb of scandium,
rhodium, indium and bismuth as internal standards. An Agilent 7500ce Inductively
Coupled Plasma - Mass Spectrometer (Agilent Technologies, Santa Clara, CA) was used
for the analysis. The ICP-MS was tuned to yield a minimum of 6000 counts per second
(cps) sensitivity for 1 ppb yttrium (89 atomic mass units), < 1.0% oxide level as
determined by the 156/140 mass ratio and < 2.0% double charged ions as determined by
the 70/140 mass ratio. Gadolinium was calibrated using a 5 point linear relationship of
the analyte:internal standard response ratio. Bismuth (209) was used as an internal
standard. Helium was used as a collision gas to control polyatomic interferences to
gadolinium. The gadolinium and internal standard mix was sourced from an outside
laboratory (Inorganic Ventures, Christiansburg, VA). The limit of detection for
gadolinium using this method is 0.0001188 part per billion.
Scanning and transmission electron microscopy with electron probe microanalysis
SEM was performed in conjunction with TEM and electron probe microanalysis
at our institutional affiliate, The Institute for Imaging and Analytical Technologies, to
characterize and quantify the distribution of gadolinium deposits in brain tissue samples.
Samples were fixed first in 10% neutral buffered formalin for 30 days. After primary
fixation, small samples (~ 1mm square for TEM and ~ 1cm for SEM) were excised and
placed into ½ Karnovsky’s fixative (2% paraformaldehyde + 2.5 % glutaraldehyde) in 0.1
M sodium cacodylate buffer (pH 7.2) at 4o Celsius until further processing. After the
secondary fixation, the samples were rinsed and dehydrated in a graded ethanol series.
The TEM samples were then infiltrated with Spurr’s resin. Ultra-thin (~80 nm)
sections were cut with a Reichert-Jung Ultracut E ultramicrotome (Reichert-Jung
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Incorporated, Depew, NY) and were collected on 75 mesh formvar coated copper grids.
Sections were stained with lead citrate and initially examined with a JEOL JEM-1230
TEM (JEOL USA, Peabody, MA) at 80 kV for image generation and orientation of
potential gadolinium locations. Once key areas were identified, grids were reexamined at
200 kV with a JEOL JEM-2100 equipped with an Oxford EDS system (Oxford,
Oxfordshire, UK) for elemental analysis.
For SEM these samples were chemically dried using hexamethyldisilazane
(HMDS) and then further air dried. Dried samples were affixed to aluminum stubs using
double sided carbon tape and viewed in a Zeiss EVO-50 VP SEM (Zeiss, Jena, Germany)
at 10 kV and 40 Pa using the back-scattered detector for imaging and Bruker EDS system
for elemental analysis.
Statistical analysis
The effect of dose on the concentration of gadolinium deposits within in the brain
was assessed using linear mixed-effects models with PROC MIXED in SAS for Window
9.4 (SAS Institute, Inc., Cary, NC, USA) by a board-certified veterinary epidemiologist.
For fixed tissues, a separate analysis was conducted for group 1, group 2, and group 1
and 2 combined. For the individual group analyses, dose, lobe, and the dose by lobe
interaction were the fixed effects in the model. In that case, dose was the only fixed
effect. Dose, group, lobe, and the dose by group, dose by lobe, and lobe by group
interaction terms were the independent variables in the combined group analyses. For
group 2, another analysis was conducted which compared the fresh and fixed tissues.
Dose, lobe, tissue type and all two-way interactions were the fixed effects in the model.
Dose was considered a continuous variable and was included as a covariate in all models.
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Dog identity was included as a random effect in all models. If the interaction terms were
not significant, they were sequentially removed with the term with the largest p-value
removed and the model refit. Differences in least squares means with the Simulate
adjustment for multiple comparisons were determined for significant main effects or
interaction terms. Diagnostic plots of residuals for each outcome were assessed to ensure
the assumptions of the statistical method had been met. An alpha level of 0.05 was used
to determine statistical significance.
Results
Subject population
Fourteen young, purpose-bred, canine research subjects of similar age and weight
(n=8 in group 1, n=5 in group 2, and n=1 in group 3), satisfied inclusion criteria for the
study. All dogs were healthy, had brain tissue that was deemed normal based on gross
and histologic examinations and were exposed to a single intravenous low-dose of
gadodiamide in vivo prior to humane euthanasia. Hepatobiliary and renal serum
biochemistry values, as well as the gadodiamide dosing scheme used in this study
population, are summarized in Tables 5.1 and 5.2. No dogs were excluded. Dogs had no
historical or current evidence of brain disease and were deemed healthy based on
physical and neurophysical examination. Dogs were therefore presumed to have a normal
and intact BBB prior to all interventions. The median weight of the subjects at the time of
enrollment, administration of the GBCA agent, and humane euthanasia, was 23.75 kg
(range=17.5–32 kg, mean=23.76 kg, IQR=8.65), and median age was 8.5 months
(range=5–13 months, mean=8.6 months, IQR=5). Five dogs were intact males, 8 were
intact females, and 1 was a spayed female.
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All dogs had minimum database baseline CBC and serum biochemistry results
within reference ranges for the species (as given in Table 5.1) and negative serum occult
HTW-Ag tests.
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Table 5.1
Group
subject
number

Hepatobiliary and renal serum biochemistry values for all dogs of groups 1,
2, and 3.
Alk Phos

ALT

T Bili

BUN

Creat

(U/L,
reference
range 11–140
U/L)

(UL, reference
range 10–90
U/L)

(mg/dl,
reference
range 0.2–
0.6 mg/dL)

(mg/dl,
reference
range 8–24
mg/dL)

(mg/dl, reference
range 0.5–1.4
mg/dL)

1

120

12

0.6

9

0.6

2

130

10

0.3

8

0.8

3

138

13

0.2

8

0.6

6

135

16

0.3

12

0.81

4

86

28

0.4

9

0.87

7

73

36

0.3

10

0.78

5

92

27

0.3

10

0.14

8

90

34

0.2

8

0.76

1

84

15

0.2

17

0.98

2

67

51

0.2

18

1.09

3

58

22

0.3

16

1.07

4

50

20

0.2

19

1.04

5

62

34

0.4

19

0.96

80

20

0.2

16

1.07

Group 1

Group 2

Group 3
1

All dogs from all groups had normal hepatobiliary and renal values.
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The 8 dogs of group 1 had negative serum titers for Ehrlichia canis, Rickettsia
rickettsii, Borellia burgdorferi, and Babesia canis and CSF West Nile virus titers. MRI of
eight dogs (group 1) demonstrated normal brain morphology, signal intensity pre-contrast
administration, and normal patterns of enhancement following the IV gadodiamide
administrations with no evidence of BBB disruption, deemed as such by a board-certified
veterinary radiologist and 3rd year imaging resident. CSF cytology in the 8 dogs of group
1 were within normal reference ranges (protein quantification <30 mg/dL with nucleated
< 5 cells/uL). Testing verified that this population purpose-bred canine subjects were
negative for such infections and that exposure to infectious agents did not occur while in
containment in the southeastern region where they were enrolled. Serum biochemistry
tests, including renal and hepatobiliary serum chemistry tests, and CBC, were within
reference range in all subjects.
Dogs of groups 1 and 2 underwent a single, IV gadodiamide exposure. Following
pre-enhanced MRI, dogs of group 1 received various low doses of IV gadodiamide 3–7
days (mean=5.4, median=5, IQR=1.5) prior to humane euthanasia. For group 1, cisternal
CSF centesis occurred under general anesthesia following conventional MRI, GBCA
administration and CEMRI (as described in detail in Chapter II). Dogs of group 2
similarly received various low doses of IV gadodiamide 8.3–8.9 hours (mean=8.6 hours,
median=8.5 hours, IQR=0.175) prior to humane euthanasia. All dogs underwent all
procedures without complication, including humane euthanasia. Post mortem, the brains
of the subjects were harvested no more than 3.5 hours (range=1–3.5 hours) following
humane euthanasia and were kept on ice during that interim. Samples were placed in
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formalin fixation and archived for 101–278 days (mean=157.8 days, median=150.5 days,
IQR=86) as shown in Table 5.2.
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0.025
0.025
0.05
0.05
0.1
0.1

6

4

7

5

8

0.0125

2

3

0.006

1

4.0

4.0

2.3

2.5

0.88

1.0

0.45

0.2

(hours)

(mL)

Group 1

tissue collection

administered

(mmol/kg)

144

120

168

144

96

72

120

168

imaging and

of GBCA

GBCA

Time between

number

Total volume

Dose of

150

151

156

157

158

274

276

278

Fixation (days)

formalin tissue

Time of

52

52

52

52

52

52

52

52

state (days)

in fresh frozen

Time of tissue

150

157

151

158

156

274

276

278

ICP-MS

/ necropsy and

tissue collection

Time between

Doses of gadodiamide as administered to dogs with information regarding tissue state, timing of sample collection
and total time between tissue collection (and necropsy) and gadodiamide administration for all dogs.

Group subject

Table 5.2
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0.05
0.1
0.1

3

4

5

1

0.0

0.05

2

Group 3

0.025

1

Group 2

Table 5.2 (Continued)
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0.0

5.9

6.1

2.9

3.4

1.5

8.6

8.6

8.7

8.5

8.8

8.5

69

69

69

69

69

69

32

32

32

32

32

32

101

101

101

101

101

101

Effect of gadolinium exposure on tissue deposition
Brain tissue remained histopathologically and grossly normal following
gadodiamide administration, and did not show any evidence of associated pathology
under light microscopy. Elemental gadolinium deposition following a single intravenous
exposure occurred at all doses administered, including the lowest fractional dose
(approximately 1/16th of the 0.1mmol/kg dose), in all dogs except for the control. All
dogs exposed, regardless of dose, demonstrated elevated levels of intracranial gadolinium
in the 6 prescribed lobar regions with concentrations ranging from 1.7 to 162.5 ng Gd/g
of brain tissue for group 1 and 67.3 to 1216.4 ng Gd/g of brain tissue for group 2 (Table
5.3). The highest mean gadolinium concentrations were seen within the cerebellum
(mean 252.5 ng/g, range 3.2–659.0 ng/g, IQR 373.7), parietal (mean 275.8 ng/g, range
19.7–911.7 ng/g, IQR 351.8), and piriform lobes (mean 200.1 ng/g, range 22.1–839.0
ng/g, IQR 313.2). Retained gadolinium in the brains of these healthy canine subjects,
quantified using ICP-MS, is shown in Table 5.3.
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27.53
4.193
7.645
20.59

2

3

4

Brainstem

80.68

24.41

10.92

32.7

Cerebellum

13.4

10.03

10.82

20.9

Frontal lobe

51.02

19.71

7.883

42.05

Parietal lobe

Deposition by lobe of brain (ng gadolinium/ g brain tissue)

Gadolinium deposition by lobe for all dogs of each group

1

Group 1

number

Subject

Group and

Table 5.3
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50.02

27.53

15.47

38.94

Piriform lobe

39.42

13.22

7.838

19.02

Thalamus

10.65
20.13
39.85

6

7

8

917.5
550.0
1216.4

1

2

3

Group 2

54.53

5

5.3 (Continued)
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360.9

382.6

220.8

94.81

63.35

28.89

162.5

100.5

95.3

68.6

36.18

21.6

1.707

32.29

290.7

343.2

308.2

62.99

29.97

20.14

79.67

289.9

375.1

335.2

54.44

33.51

22.14

83.12

166.7

185.2

67.3

49.34

29.35

15.52

51.93

3.2

363.6

658.9

Deposition given in ng gadolinium/g brain tissue

1

5.3

927.6

5

Group 3

971.1

4

5.3 (Continued)
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0

102.9

112.6

3.1

716.2

910.3

2.4

330.7

839.0

1.4

174.1

222.6

Statistical model with group 1 and group 2 dogs
Gadolinium tissue concentration in fixed tissues was significantly affected by the
group by lobe (p<0.001) interaction in the analysis that combined group 1 and 2 dogs
(Table 4). The least square means (lsmeans) of gadolinium concentrations for group 1
dogs were significantly less than group 2 dogs for brain stem (p<0.001), cerebellum
(p=0.025), parietal lobe (p<0.001), and piriform lobe (p=0.002). There were no
significant differences in lsmeans of gadolinium concentrations between groups for
frontal lobe white matter (p=0.999) or thalamus (p=0.975). There were no significant
differences of the lsmeans between lobes of the brain in group 1 dogs (p>0.999). In group
2, gadolinium concentrations were greater in the brainstem than in the cerebellum
(p<0.001), frontal lobe white matter (p<0.001), parietal lobe (p<0.001), piriform lobe
(p<0.001), and thalamus (p<0.001). The gadolinium concentrations in the cerebellums of
group 2 dogs were significantly greater than in the frontal lobe white matter (p=0.019)
but were not significantly different than in the parietal lobe (p=0.942), piriform lobe
(p=1.000), or thalamus (p=0.150). Concentrations in the parietal lobe of group 2 dogs
were significantly greater than in frontal lobe white matter (p<0.001) and thalamus
(p=0.003) but were not significantly different from concentration in the piriform lobe
(p=0.996). Concentrations in the piriform lobe of group 2 dogs were significantly greater
than in frontal lobe white matter (p0.004) and approaching the alpha level for thalamus
(p=0.051). Concentrations in the frontal lobe white matter and thalamus were not
significantly different (p=0.999). The group by dose interaction was also significant
(p<0.001) in the analysis that combined group 1 and 2 dogs. The regression plots of
tissue concentration by dose for group 1 and group 2 dogs are presented in Figure 5.1.
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Regression lines of gadolinium concentrations (ng/g) by dose (mmol/kg)
for group 1 and group 2 dogs.
The gadolinium concentrations are the values predicted by the linear mixed model with
dose, group, lobe, and the group by lobe and group by dose interactions as fixed effects
and dog identity as a random effect. Data points are the actual measured values of the
gadolinium concentrations as determined by ICP-MS.
Model with group 1 dogs
Due to the significant interactions with group, data from group 1 and 2 dogs were
analyzed separately. In group 1 dogs, gadolinium concentration in fixed tissue was
significantly affected by the dose by lobe interaction (p<0.001). Within the brain lobes,
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the response to dose for cerebellum was significantly different than for the other brain
lobes (p<0.001). The regression plots of tissue concentration by dose for each of the lobes
is shown in Figure 5.2.

Regression lines of gadolinium concentrations (ng/g) by dose (mmol/kg)
for each brain lobe of group 1 dogs.
The gadolinium concentrations are the values predicted by the linear mixed model with
dose, lobe, and the lobe by dose interaction as fixed effects and dog identity as a random
effect. Data points are the actual measured values of the gadolinium concentrations as
determined ICP-MS.
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Model with group 2 dogs
In group 2 dogs, gadolinium concentration in fixed tissue was significantly
affected by lobe (p<0.001) (Table 5). Gadolinium concentration were greater in the
brainstem than in the cerebellum (p=0.005), frontal lobe white matter (p<0.001), parietal
lobe (p=0.043), piriform lobe (p=0.009), and thalamus (p<0.001). The gadolinium
concentration in the cerebellums of group 2 dogs were not significantly greater than in
the frontal lobe white matter (p=0.210), parietal lobe (p=0.941), piriform lobe (p=1.000),
or thalamus (p=0.465). Concentrations in the frontal lobe white matter of group 2 dogs
were significantly lower than in the parietal lobe (p=0.031) but were not significantly
different from those of piriform lobe (p=0.127) or thalamus (p=0.995). Concentrations in
the parietal lobe of group 2 dogs were not significantly different than those in the
piriform lobe (p=0.989) or thalamus (p=0.104). Gadolinium concentrations in the
piriform lobe of group 2 dogs were not significantly different than concentrations in the
thalamus (p=0.314). Gadolinium tissue concentrations were also significantly affected by
dose (p<0.001), but there was not a significant dose by lobe effect (p=0.123) as was seen
in group 1 dogs. The regression plot of gadolinium concentration by dose for the group 2
dogs is shown in Figure 5.3.
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Regression line of gadolinium concentrations (ng/g) by dose (mmol/kg) for
group 2 dogs.
The gadolinium concentrations are the values predicted by the linear mixed model with
dose and lobe as fixed effects and dog identity as a random effect. Data points are the
actual measured values of the gadolinium concentrations as determined by ICP-MS.
Model with group 2 dogs comparing tissue type
No significant differences in the gadolinium concentrations were found between
fixed and fresh tissues from group 2 dogs (p=0.430). There was a significant effect on
concentrations by brain lobe (p<0.001), irrespective of tissue type or dose (Table 5.3).
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Gadolinium concentrations were not significantly greater in the brainstem than in
cerebellum (p=0.068) or parietal lobe (p=0.266). They were significantly greater in the
brainstem than in frontal lobe white matter (p<0.001), piriform lobe (p=0.007), and
thalamus (p<0.001). The gadolinium concentrations in the cerebellum were significantly
greater than in the frontal lobe white matter (p=0.016) but not in parietal lobe (p=0.987),
piriform lobe (p=0.955), or thalamus (p=0.097). Concentrations in the frontal lobe white
matter were significantly lower than in the parietal lobe (p=0.003) but were not
significantly different from those of piriform lobe (p=0.144) or thalamus (p=0.982).
Concentrations in the piriform lobe were not significantly different than those in the
parietal lobe (p=0.673) or thalamus (p=0.474). Gadolinium concentrations in the parietal
lobe were significantly greater than concentrations in the thalamus (p=0.019).
Gadolinium tissue concentrations were also significantly affected by dose (p=0.003).
The regression plot of gadolinium concentration by dose from the model which included
tissue type and lobe for the group 2 dogs is shown in Figure 5.4.
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Regression line of gadolinium concentrations (ng/g) by dose (mmol/kg) for
group 2 dogs.
The gadolinium concentrations are the values predicted by the linear mixed model with
tissue type, dose and lobe as fixed effects and dog identity as a random effect. Data points
are the actual measured values of the gadolinium concentrations as determined by ICPMS.
For dogs of group 1, gadodiamide dose administered was strongly positively
correlated with parenchymal gadolinium tissue concentration (R-square 0.73); however,
for dogs of group 2, dose was not correlated with parenchymal gadolinium deposition.
There was no statistical correlation between age and deposition, weight and deposition, or
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gender and deposition. The deposition by lobe and deposition by dose did not correlate
between dogs of group 1 and group 2 for either fresh or fixed brain tissue.
Localization of gadolinium within neuronal tissue and assessment of histologic
change
When evaluated with SEM, gadolinium was not detected in any of the tissue
samples. Six lobar samples from dogs administered either 0.1 mmol/kg (n=2) or 0.05
mmol/kg (n=1) gadodiamide were evaluated with TEM. TEM demonstrated several
angular, irregularly shaped structures with a mean length of 1009 nm (range 683–1360
nm), throughout the examined tissue. These structures displayed sharp margins. For
group 1 dogs, all structures were within the vascular endothelial cells; for group two
dogs, however, some were membrane bound within the neuropil. This is likely consistent
with cellular pinocytosis.100 These structures demonstrated an L-series K-edge of 2.111,
consistent with gadolinium, and corresponded to approximately 0.19% of the weight of
the sample. The membrane around the gadolinium confirmed they were intracellular
within the neuropil, however exact cell types containing the gadolinium could not be
determined due to the sample being unstained to avoid contamination. Other elements
found in the samples included carbon, oxygen, sodium, magnesium, silicon, sulfur,
chlorine, cobalt, nickel, copper, and lead.
Discussion
The author reports herein gadolinium deposition in brain tissue of healthy dogs
with normal renal and hepatobiliary function following a single IV exposure of fractional
gadodiamide doses. No previous studies have explored the neural deposition of
gadodiamide in dogs, nonhuman primates or in people lacking evidence of serious
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systemic disease and multiorgan failure following a single administration of a GBCA.
Herein the author describes some of the features of neuronal deposition following the
intravenous deposition of fractional doses of gadolinium (gadodiamide), ranging from
0.006–0.05 mmol/kg, which are well below the recommended (and reported) human and
companion animal dosing schemes.
Gadolinium deposition
Gadolinium deposits were found within the brains of all healthy canine subjects
evaluated, at all doses, following a single IV administration of the non-ionic linear
GBCA, gadodiamide. Brain tissue deposits were noted after administration of doses
lower than the established recommended human dose range in all but the control dog.
These depositions were seen within the vascular endothelium in 3-7 days (in the case of
group 1 dogs) and within the neuropil in 8.3–8.9 hours (in the case of the group 2 dogs)
post-intravenous exposure to gadodiamide. When compared to ex vivo studies in people,
results of this study show the pattern of deposition in brain tissue of dogs of group 1
closely followed those recently described in people, specifically dose dependency in the
thalamus, white matter of the frontal lobe, and cerebellum.105,166 Gadolinium deposition
occurred despite the fact that, in the evaluated population of dogs, dosing and
administration were limited to a single, 0.1 mmol/kg or fractional dose. This information
complements earlier studies that describe deposition of gadolinium within the human
brain of repeatedly scanned clinical patients having both single and multiple doses of a
GBCA for CEMRI despite the presumption of normal BBB integrity.113,166 Although all
of the patients in those studies had systemic illnesses, many had normal renal and
hepatobiliary function and normal estimated GFR.105,166 Prior studies have used ICP-MS
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to show gadolinium deposition in the bone from patients undergoing total hip
arthroplasties and to report gadolinium deposition in the femora of patients with normal
renal function.165,175 Further, ICP-MS was used to quantify gadolinium in the skin in 13
patients suffering from nephrogenic systemic fibrosis, and resulted in a mean gadolinium
concentration of 71.4 µg/g in these patients.148 Additionally, studies investigating
intracranial gadolinium deposition in people administered both linear and macrocyclic
agents were quantified using ICP-MS.105,113,166 Historically, investigations in people
having parenchymal depositions had serious systemic illness and succumbed to their
diseases regardless of whether or not hepatobiliary and renal function tests were
normal.105,113,166 Results of the current study confirms that intracranial gadolinium
deposition occurs in the vascular endothelium and neuropil of the brains of healthy dogs,
with normal hepatic and renal function, as early as 3 days and 8 hours, respectively,
following IV injection. Previous work in murine models confirmed deposition in healthy
subjects of these species; however, this deposition occurred following 20 injections at 0.6
mmol/kg, whereas the current study shows deposition following a single injection of a
fractional dose ranging from 0.006–0.1 mmol/kg.155
Gadolinium deposition did not occur in the fresh tissues of the control dog in this
study via ICP-MS. In the fixed samples in the same dog, however, trace amounts of
gadolinium were quantified within the parietal lobe (3.1 ng/g), piriform lobe (2.4 ng/g),
and thalamus (1.4 ng/g) lobes. This finding is in concert with recent results from other
studies in which control patients (having had no previous exposure to gadolinium by way
of GBCA administration for CEMRI, and brain sample quantification by way of ICPMS), demonstrated trace amounts of gadolinium deposition (up to 0.2 ng/g) in numerous
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brain regions.113 The results from the control dog in the current study were, as in the
previous study, orders of magnitude lower than the results from the exposed dogs. The
investigating physicians of the previous study attributed this finding to small
environmental exposures.113 Given inability to document gadolinium deposition in fresh
tissues from the same (control) patient, specific consideration in this study is also given
to contamination during preparation for fixation and/or (mechanical) residuals during any
step of pre-processing on surfaces or at any point during ICP-MS.
Dose dependency
The degree of gadolinium deposition in the canine subjects of this study was dose
dependent for all lobes in all dogs of group 1, following a linear regression with an Rsquare value of 0.73. These dogs were given the drug 3–7 days prior to humane
euthanasia suggesting that once administered, deposition may begin to occur, at any dose,
sooner than 48 hours following administration. Contrary to expectations, the results of
group 2 contradicted the lobar affinity and dose deposition profiles of those of group 1 in
that dose dependency was not observed, and a linear regression could not be fit to these
data. This result can be attributed to the difference in sampling timing between the two
groups of dogs. Dogs in group 1 were exposed to gadolinium 3–7 days prior to
euthanasia, whereas dogs in group 2 were exposed to gadolinium only 8.3–8.9 hours prior
to euthanasia. Previous pharmacokinetic studies in both people and animals, using
numerous GBCAs, have suggested an extracellular distribution of gadolinium, with 90–
99% of the gadolinium being excreted unchanged in the urine within 72 hours of
administration, and the remaining being cleared via hepatic clearance in the bile.100,101,176
The findings of the current study and other recent studies in people demonstrating
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deposition in both the brain and the bone, suggests a more complicated pharmacokinetic
behavior than what was previously believed.165,166,175 Although conjectural, and an idea
that warrants further investigation, it is possible that some degree of redistribution of
gadolinium or gadolinium chelate occurs sometime between 8 and 48 hours following
intravenous administration, which may have resulted in the difference in deposition
pattern seen between the two groups of dogs in this study.
The author found that the brains of dogs administered a single, fractional dose of
gadolinium contained an average of 0.028% of the total dose (group 1=0.02%, group
2=0.04%) over the 6 lobes of brain evaluated per gram of brain mass, representing only a
small portion of the total accumulation for a given dog within the brain.
Prior studies
No published studies are available for which to compare the results of the current
study. The current study complements historical observations of several studies in which
intracranial gadolinium deposits were present in people having had single or multiple
doses of GBCAs.105,113,156,166,177 Similarly, deposition of gadolinium occurred in all
healthy dogs having no clinical evidence of hepatobiliary or renal dysfunction. The
results herein provide direct evidence that gadolinium begins to deposit within the
neuropil regardless of dose and following a single 0.1 mmol/kg or fractional dose
exposure to gadodiamide compared to the control subject that received a placebo small
volume of saline. The control also served to validate quantification methods and provide
a comparison for SEM and TEM evaluation. The presence of gadolinium in the neuropil
within hours (range 8.3–8.9 hours) following the administration of fractional doses
demonstrates that deposition may not be limited to that acquired by way of repository
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accumulations in the bone matrix by way of slow release and organ reuptake of a
sequestered pool of gadolinium.165,175 In addition, the results herein support potential
early widespread interstitial brain parenchymal exposure (between 8.8–8.9 hours) and
vascular endothelial (at 3–7 days) and biodistribution of the unexcreted fraction of
gadolinium residuals, and represent the likelihood of more complex pharmacokinetics
than what is currently understood. Furthermore, the presence of gadolinium in the normal
brain tissue of dogs with no physical or MR imaging evidence of BBB disruption
challenges the current understanding of how GBCAs interact with an intact BBB in
healthy subjects with no historical or current brain afflictions, or other systemic diseases.
Physiology
The integrity of the BBB and its permeability is affected to varying degrees by
multiple disease processes, which is why purpose-bred, healthy dogs with no current or
historical evidence of brain disease were evaluated in this study. When the BBB is
disrupted, or when abnormal vascularity is present, gadodiamide can accumulate within
lesions such as neoplasms, abscesses, and subacute infarcts.178 McDonald et al evaluated
formalin-fixed, cadaveric samples of brain (from regions of brain that were at a minimum
of 2 cm from external beam radiation exposed tissue, or 4 cm from a brain lesion)
obtained from gadolinium exposed people with historical multiple gadodiamide
administrations with x-ray microanalysis/densitometry.166 That study presumed normal
BBB integrity and found that 18%–42% of the administered gadolinium had crossed the
BBB with deposition into the neural tissue interstitium.166 The remainder of the agent was
sequestered in non-uniform fashion within the endothelial wall of neuronal capillaries in
large clustered foci, similar to results from groups 1 and 2 in the current study.166
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The mechanism by which gadolinium deposits within the normal brain is poorly
understood. Brain-wide paravascular or glymphatic CSF and interstitial fluid (ISF)
exchange for clearance of solutes and waste using dynamic CEMRI is described in
murine models.179 Gadolinium allows for the identification of waste influx at key
anatomical influx nodes, specifically the pituitary and pineal gland recesses.179 In
addition, kinetic parameters that characterize influx and clearance routes of paramagnetic
contrast agents are defined, and glymphatic CSF and ISF exchange and solute clearance
is generally described.179 CSF secretion and reabsorption is not limited to traditional
modeling of CSF secretion and the historical understanding of kinematics wherein only
the antegrade flow of CSF occurs.180
In mice, a large portion of subarachnoid CSF recirculates throughout the brain
parenchyma along paravascular spaces and exchanges with the interstitial fluid along
such routes, and through the interstitium, by way of transglial water movement through
astrocytic aquaporin-4 (AQP4) water channels, facilitating the clearance of interstitial
solutes.180 The retrograde paravascular influx of paramagnetic contrast agents from the
subarachnoid space rapidly enters the brain parenchyma by way of Virchow-Robin
spaces along the para-arterial channels.180 In the author’s opinion, these regions and
pathways provide not only a conduit for solute uptake from the brain, but potentially one
for deposition to the brain parenchyma. It is plausible, although unproven, that the
clearance pathways captured by gadolinium enhanced MRI may elucidate the potential
pathway of parenchymal exposure and therein, deposition (Jennifer Gambino, personal
communication, January 17, 2017).
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Important factors to consider that may or may not contribute to the deposition of
gadolinium within the parenchyma are the physical state of gadolinium at the time of
parenchymal exposure, the physiologic mechanisms or events that drive ionization
(which may be unique to individual patient and disease state and over all sequestration),
deposition, and neuroanatomic affinity of the elemental gadolinium and the chelate.
These details remain incompletely understood.166 Further, the physical state of the
element cannot be speciated in tissue by currently described methods.105,113,166 Chelates
are historically considered stable pharmaceutical entities. Results of the current, and other
recent historical studies support the contrary.113,166 GBCAs do not bind to human serum
proteins in vitro and have no biotransformation (or evidence of metabolism) occurring in
urine and fecal matter.89,181 In a murine model, radiocarbon tracing of the GBCA ligand
demonstrated that, for a given organ compartment, elimination of the compound depends
on the respective organ with clearance of gadolinium and the ligand being identical
(when measured independently).89,182 Thus, the conclusion that disassociation does not
take place is erroneously based on a premise that lacks more specific speciation of the
excreted individual components (the ligand and the ion, respectively). Further, it is
highly plausible that in vitro findings cannot be translated over to the in vivo
pharmacokinetics of these agents.89,183
In general, GBCAs are analogous to iodinated radiographic agents in that they
have rapid renal excretion (unchanged) by way of glomerular filtration, a short half-life
(1–2 hours), and greater than 90% of an administered dose can be recovered from the
urine 3 hours following IV administration.87 In people and animals, the pharmacokinetic
parameters of gadodiamide are not well known, and detectable biotransformation or
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decomposition of the agent is not previously reported.184 GBCAs were, since the
inception of their use, not thought to cross the intact blood brain barrier and thus were
presumed not to accumulate in normal brain or in lesions that do not have an abnormal
BBB such as cysts and mature post-operative scar tissue.184 In normal subjects, when
administered intravenously, gadodiamide conforms to a two-compartmental
(extracellular) model with mean distribution and elimination half-lives (reported as a
mean +/– SD) of 3.4 +/– 2.7 minutes and 77.8 +/– 16 minutes, respectively.184 Within
twenty-four hours following administration, gadodiamide is eliminated almost entirely in
the urine (95.5% +/– 5%), with nearly identical renal and plasma clearance rates of 1.7
and 1.8 mL/min/kg, respectively, and a volume of distribution similar to that of
extracellular water (approximately 200 +/– 61 mL/kg).184
Study limitations
The current study had several limitations. The sample numbers were small, and
dogs evaluated were young and limited to the age range we described. The number of
dogs was limited by number of available dogs for terminal surgical laboratories, the
ethical and monetary expense of purpose-bred dogs and cost of MR evaluation. These
factors often preclude large prospective studies of this nature in veterinary medicine.
Limitations in subject number lead to limitations in the choice of dosing scheme(s)
investigated. A larger subject pool would have likely reduced the variability of
measurements amongst samples and would have lent greater power to the study.
Additionally, the author did not investigate the typical higher end of the dose range
administered to people and companion animals (0.2–0.3 mmol/kg). Clinical protocols for
GBCA use as established by the author’s institution do not exceed doses beyond 0.1
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mmol/kg in people or companion animals undergoing CEMRI. Thus, the author chose to
evaluate levels of accumulation for frequently administered doses of the veterinary
patients seen at the author’s institution. Only one control dog was available for
verification of analyses. The author concludes that a negative control sufficiently
addresses the potential for natural and/or environmental exposure in these dogs and
verifies the techniques used. Levels of gadolinium deposition were not quantified in
entirety (i.e. grams of Gd/entire brain) for each of the subjects, nor was deposition of
gadolinium in other organs evaluated. This limitation was due to limited financial
resources, and there was concern that if these analyses were performed, the testing may
undermine attempts to discover data supporting dose dependency, neurotropic changes
and regional neuroaffinity. Because the current study was limited to a single linear
GBCA, the findings herein are likely not directly applicable to non-linear or macrocyclic
GBCAs. Although preliminary hepatobiliary and renal function of all dogs was normal,
estimated GFR (eGFR) calculation, nuclear scintigraphy or computed tomographic GFR
estimation were not performed. A relevant eGFR estimate equation is not available across
the breeds or veterinary species and the author had no reason to suspect underlying renal
insufficiency in this population based on laboratory and clinical evaluation. Further, urine
specific gravity and urinalyses results were not obtained in the evaluated dogs.
Regardless, the author had no reason to believe any of the dogs had impaired renal
function. Finally, the physical chelation state of the neuronal gadolinium deposited in
these dogs was not determined. This is a technological limitation, as speciation of
neuronal gadolinium deposits in formalin-fixed tissue is not currently available.89,166
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Conclusion
In conclusion, a single, full or fractional, IV administration of gadodiamide is
associated with dose dependent deposition in the neuropil of neuronal tissues, unrelated
to renal and hepatobiliary function. The author and cohorts were able to determine that
the gadolinium was membrane bound and therefore within the neuropil. The exact cell
type, however, could not be determined due to secondary mechanical distortion of the
cell, using an unstained sample and not focusing the electron microscope to preserve the
sample. Although a goal of the study was to describe the deposition and lobar affinities
for gadodiamide administered at two time points in healthy dogs, the histological
phenotype of deposited gadolinium was not found.
Admittedly, the discovery of parenchymal brain gadolinium deposits are likely
not pertinent to the clinical outcome of companion animals receiving GBCAs with regard
to long-term deleterious cognitive or physiologic effects, and to date, extensive evidence
and literature as to what those effects may be in people has yet to surface. Furthermore, it
will likely not be feasible to assess subtle clinical signs related to low or clinical dose
exposures to GBCAs in veterinary patients.
A goal of a separate study, however, (as described in Chapter IV) was to find
lower clinical dosing schemes that would provide adequate conspicuity of normal brain
structures with CEMRI given historical relationship of dose and dose dependent adverse
events.140-142 This lead to the discovery that a single, fractional dose as low as 0.006
mmol/kg has the potential to deposit within the brains of healthy, otherwise
uncompromised dogs. The findings of the study herein are translatable to people. Dogs
have been diagnosed with approximately 300 of the 400 intracranial diseases described in
141

people, making them a viable model for human intracranial disease.185 Currently, no
evidenced based literature exists defining clinical syndromes attributable solely to
gadolinium exposure in people or animals. The dog however, can serve as a viable in vivo
translational model for future investigation of deposition profiles of various GBCAs and
chelate agents. This study provides transformative data that may be relevant to the
continued use of gadodiamide (and linear GBCAs) in routine CEMRI studies for both
clinical purposes and for research in people.
Results from the current study may aid clinicians in discretionary decision making
with regard to choice of GBCA (i.e. linear versus macrocyclic, or otherwise) and may
mitigate future use of linear GBCAs in healthy human subjects participating in
prospective MRI studies, in pediatric patients, and in those patients in which the use of a
GBCAs is not essential to patient care, follow up or quality of life. Potential clinical
implications or ramifications of gadolinium deposition and accumulation in the brain and
other organs are yet to be determined. Future research following the outcomes of patients
having already received these agents are warranted in order to determine if gadolinium
retention poses a safety risk or causes long-term health consequences in both people and
animals. The work herein may serve as an impetus for the following: evaluating other
classes of GBCAs and the use of gadolinium nanoparticles for CEMRI, investigating
novel and safer methods of chelation, investigating mechanisms by which GBCAs cross
the BBB, and exploring alternative means of increasing the sensitivity and specificity of
MR imaging while limiting the use of linear GBCAs to clinical cases necessitating the
agents.
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LIST OF ABBREVIATIONS
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Ala –Alanine
B0 – Main magnetic field or Mz (z) magnetization axis
BBB – Blood brain barrier
CEMRI – Contrast enhanced magnetic resonance imaging
Cho – Choline
Cr – Creatine
CSF – Cerebrospinal fluid
FID – Free induction decay
FLAIR – Fluid attenuation inversion recovery
FWHM – Full width half maximum
GABA – ϒ–amino butyric acid
GBCA – Gadolinium–based contrast agent
Gd – Gadolinium
Glu – Glutamate
Gln – Glutamine
Glx – Glutamate/glutamine complex
Gsh – Glutathione
1

H – Proton

Lac – Lactate
Lip – Lipids
mI – Myo-inositol
MR – Magnetic resonance
MRI – Magnetic resonance imaging
161

MRS – Magnetic resonance spectroscopy
MRSI – Magnetic resonance spectroscopic imaging
ms – milliseconds
MVS – Multi-voxel spectroscopy
NAA – N-acetyl aspartate
NEX – Number of signal averages
NMR – Nuclear Magnetic Resonance
PRESS – Point resolved spectroscopy
RF – Radiofrequency
STEAM – Stimulated echo acquisition mode
SVS – Single-voxel spectroscopy
T1 – Longitudinal relaxation time
T2 – Transverse relaxation time
Tau – Taurine
TE – Time to echo or echo time
TR – Time to repitition
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MR SPECTROSCOPIC METABOLITES OF INTEREST
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MRS metabolites of interest, spins, and clinical importance

2.0

3.0
3.2

N-acetyl aspartate
(NAA)

Creatine (Cr)

Choline (Cho)

3.5, 3.7

1.3

Myo-inositol (mI)

Lactate (Lac)

Product of anaerobic glycolysis (low levels in normal brains). Increased with hypoxemic
events, cell death and necrosis. Can be increased in brain tumors and infarction.

Pentose sugar, involved in the inositol triphosphate intracellular second messenger system.
Osmolyte and astrocyte biomarker. Seen with abnormal metabolism or damaged
membranes. Elevated with mannitol administration.

Complex peak of several choline containing membrane & brain inflammatory markers.
Elevations occur with inflammation and malignancy. Cell membrane marker involved in
synthesis and degradation.

2nd tallest peak in the grey matter spectra. Brain energy marker.

Most prominent peak. Quantitative for neuronal viability. Indicates grey matter neuronal
number and white matter axonal density. Present only in neurons, axons, and dendrites.

Metabolite of Interest ppm spin at Relevance
3T
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3.4

Taurine (Tau)

Spins of various brain metabolites (in ppm) acquired as part of a magnetic resonance spectrum, with their associated properties,
clinical relevance, and use. Adapted from Soares and Law (2009) and Baker et al (2010).31,186

Osmoregulator and modulator of neurotransmitter action. Suggests aggressive tumor
growth, as with medulloblastoma.

Non-essential amino acid. Not usually present. Present in meningiomas

1.48

Alanine (Ala)

Normal component of scalp, skull & cell membranes. Increased with cell death. Can be a
voxel contaminant.
Excitatory neurotransmitters (glutamate is excitatory and plays a role in mitochondrial
metabolism; glutamine plays a part in detoxification and regulates neurotransmitter
activity).

0.9–1.4

Glutamine/Glutamate 2.2–2.4
(Glx)

Lipids (Lip)

Table B.1 (Continued)
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BRAIN MRI PROTOCOLS
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Typical MRI acquisition protocols
Typical conventional MRI acquisition protocol was as follows:
Matrix: 512x512
NEX (Number of signal averages): 2
Reconstruction diameter: 140 mm
Slice thickness: 2.4 mm
Slice interval: 2.4 mm
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Figure C.1
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MRI acquisition parameters for the eight dogs described in Chapters II, IV, and group 1 of IV

Typical MR sequences
Typical minimum MR sequences and acquisition parameters acquired for
all dogs in Chapters II and IV, and group 1 of Chapter V
Sequence

Sagittal T1-W fast spoiled

Echo Time [TE]

Repetition time

Flip angle

(ms)

[TR] (ms)

(degrees)

3.7

8.3

20

3.7

8.3

20

126.1

7777

90

6

545

18

3.7

8.3

90

gradient echo (FSPGR)
Transverse T1-W fast
spoiled gradient echo
(FSPGR)
Transverse T2-W fluid
attenuation inversion
recovery (FLAIR)
Transverse T2* fast
gradient echo (FGRE)
Transverse T1-W fast
spoiled gradient echo
(FSPGR) post-contrast
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